WO2019055807A1 - Zika virus rna vaccines - Google Patents

Zika virus rna vaccines Download PDF

Info

Publication number
WO2019055807A1
WO2019055807A1 PCT/US2018/051120 US2018051120W WO2019055807A1 WO 2019055807 A1 WO2019055807 A1 WO 2019055807A1 US 2018051120 W US2018051120 W US 2018051120W WO 2019055807 A1 WO2019055807 A1 WO 2019055807A1
Authority
WO
WIPO (PCT)
Prior art keywords
vaccine
zikv
seq
rna
subject
Prior art date
Application number
PCT/US2018/051120
Other languages
French (fr)
Inventor
Giuseppe Ciaramella
Sunny HIMANSU
Original Assignee
Modernatx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Modernatx, Inc. filed Critical Modernatx, Inc.
Priority to EP18855540.3A priority Critical patent/EP3681514A4/en
Publication of WO2019055807A1 publication Critical patent/WO2019055807A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • ZIKV Zika virus
  • ZIKV Persistent ZIKV infection can occur, as viral RNA has been detected in semen, sperm, and vaginal secretions up to 6 months following infection.
  • ZIKV is now a global disease with locally-acquired and travel-associated transmission through multiple routes in the Americas, Africa, and Asia. The emergence of ZIKV infection has prompted a global effort to develop safe and effective vaccines.
  • ZIKV Zika virus
  • JEV Japanese encephalitis virus
  • RNA vaccines that comprise a 5' UTR, an ORF encoding a JEV signal peptide fused to a ZIKV prME protein, and a 3' UTR.
  • the 5' UTR is selected from SEQ ID NO: 13 and SEQ ID NO: 14.
  • the ORF comprises a sequence selected from SEQ ID NOs: l-6.
  • the 3' UTR is selected from SEQ ID NO: 15 and SEQ ID NO: 16.
  • the JEV signal peptide comprises the following sequence:
  • the JEV signal peptide is encoded by the following sequence: AUGUGGCUGGUGUCCCUGGCCAUCGUGACA GCCUGUGCUGGCGCC (SEQ ID NO: 19).
  • RNA vaccine comprising an open reading frame (ORF) encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to induce in the subject a ZIKV prME- specific immune response, wherein the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 10-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
  • the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 20-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
  • the methods comprise administering to a subject a RNA vaccine comprising an ORF encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to reduce viral load in the subject by at least 80%, relative to a control, at 3- 7 days following exposure to ZIKV, wherein the control is the viral load in a subject administered a ZIKV RNA vaccine lacking the JEV signal sequence.
  • the methods comprise administering to a subject a RNA vaccine comprising an ORF encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to induce in the subject a ZIKV prME-specific immune response, wherein efficacy of the RNA vaccine is at least 80% relative to unvaccinated control subjects.
  • FIG. 1 is a graph showing the viral yield (logio focus forming units (FFU)/ml) 3, 4, 5, 6 and 7 days post challenge (with ZIKV) in non-human primates (NHPs) vaccinated with 10 ⁇ g, 50 ⁇ g, or 200 ⁇ g ZIKV mRNA vaccine.
  • Vaccine 'mRNA- 1325' encodes an IgE signal peptide fused to ZIKV prME.
  • Vaccine 'mRNA-1893' encodes a JEV signal peptide fused to ZIKV prME.
  • a single 200 ⁇ g dose of the mRNA-1325 vaccine confers nearly complete protection.
  • the mRNA-1893 vaccine outperforms the mRNA-1325 vaccine in this model by at least 20x.
  • FIG. 2 includes graphs showing neutralizing antibody titers (EC50 fold change relative to week 8) obtained from the same NHP experiments described in FIG. 1.
  • Zika virus Zika virus
  • Zika virus is a member of the Flaviviridae virus family and the flavivirus genus. In humans, it causes a disease known as Zika fever. It is related to dengue, yellow fever, West Nile and Japanese encephalitis, viruses that are also members of the virus family Flaviviridae. ZIKV is spread to people through mosquito bites. The most common symptoms of ZIKV disease (Zika) are fever, rash, joint pain, and red eye. The illness is usually mild with symptoms lasting from several days to a week. There is no vaccine to prevent, or medicine to treat ZIKV.
  • RNA vaccines e.g., mRNA vaccines
  • UTR 5' untranslated region
  • ORF open reading frame
  • JEV signal peptide fused to a ZIKV prME protein a ZIKV ribonucleic acid
  • 3' UTR a ZIKV ribonucleic acid vaccines
  • the ZIKV RNA vaccines comprise a polyA tail.
  • a 5' UTR is region of an mRNA that is directly upstream (5') from the start codon
  • a 5' UTR does not encode a polypeptide (is non-coding).
  • a 5' UTR of the present disclosure comprises a sequence selected from SEQ ID NO: 13 and SEQ ID NO: 14.
  • a 3' UTR is region of an mRNA that is directly downstream (3') from the stop codon (the codon of an mRNA transcript that signals a termination of translation) A 3' UTR does not encode a polypeptide (is non-coding).
  • a 3' UTR of the present disclosure comprises a sequence selected from SEQ ID NO: 15 and SEQ ID NO: 16.
  • a polyA tail is a region of mRNA that is downstream, e.g., directly downstream, from the 3' UTR and contains multiple, consecutive adenosine monophosphates.
  • the polyA tail functions to protect mRNA from enzymatic degradation, e.g., in the cytoplasm, and aids in transcription termination, export of the mRNA from the nucleus, and translation.
  • a polyA tail may comprise, for example, 10 to 300 adenosine monophosphates.
  • a polyA tail may comprise 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 adenosine monophosphates.
  • a polyA tail comprises 50 to 250 adenosine monophosphates.
  • a polyA tail comprises 100 adenosine monophosphates.
  • the ZIKV RNA vaccine comprises 5' terminal cap, for example, 7mG(5')ppp(5')NlmpNp.
  • an open reading frame is a continuous stretch of DNA or RNA beginning with a start codon (e.g., methionine (ATG or AUG)) and ending with a stop codon (e.g., TAA, TAG or TGA, or UAA, UAG or UGA).
  • an ORF of the present disclosure is selected from SEQ ID NO: l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6.
  • the ORF comprises the sequence of SEQ ID NO: l.
  • the ORF comprises the sequence of SEQ ID NO:2.
  • the ORF comprises the sequence of SEQ ID NO:3.
  • the ORF comprises the sequence of SEQ ID NO:4.
  • the ORF comprises the sequence of SEQ ID NO:5.
  • the ORF comprises the sequence of SEQ ID NO:6.
  • the ZIKV RNA vaccines (e.g., mRNA vaccines) of the present disclosure encode a JEV signal peptide (e.g., SEQ ID NO: 18) fused (in frame) to a ZIKV prME protein.
  • the particular prME sequence may be from any ZIKV strain, for example those strains as are known in the art or as otherwise described herein, such as a Brazilian strain, a Micronesian strain, or an African strain. Within the Zika family, there is a high level of homology within the prME sequence (>90%) across all strains so far isolated.
  • the M and E proteins are on the surface of the viral particle. Neutralizing antibodies predominantly bind to the E protein, the preM/M protein functions as a chaperone for proper folding of E protein and prevent premature fusion of E protein within acidic compartments along the cellular secretory pathway.
  • the ZIKV prME protein comprises a sequence selected from SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.
  • the ZIKV prME protein comprises the sequence of SEQ ID NO:7.
  • the ZIKV prME protein comprises the sequence of SEQ ID NO:8.
  • the ZIKV prME protein comprises the sequence of SEQ ID NO:9. In some embodiments, the ZIKV prME protein comprises the sequence of SEQ ID NO: 10. In some embodiments, the ZIKV prME protein comprises the sequence of SEQ ID NO: 11. In some embodiments, the ZIKV prME protein comprises the sequence of SEQ ID NO: 12.
  • ZIKV RNA vaccines encode a JEV signal peptide fused to a prME protein.
  • Signal peptides comprising the N-terminal 15-60 amino acids of proteins, are typically needed for the translocation across the membrane on the secretory pathway and, thus, universally control the entry of most proteins both in eukaryotes and prokaryotes to the secretory pathway.
  • the signal peptide of a nascent precursor protein directs the ribosome to the rough endoplasmic reticulum (ER) membrane and initiates the transport of the growing peptide chain across it for processing.
  • the JEV signal peptide of the present disclosure comprises the sequence of SEQ ID NO: 18.
  • a RNA (e.g., mRNA) of a ZIKV RNA vaccine of the present disclosure is chemically modified.
  • at least 80% of the uracil in the ORF may have a chemical modification selected from Nl-methyl-pseudouridine and Nl-ethyl- pseudouridine.
  • at least 85%, at least 90%, at least 95% or 100% of the uracil in the ORF have a chemical modification.
  • the chemical modification is in the 5-position of the uracil.
  • At least one RNA (e.g., mRNA) of the ZIKV RNA vaccines of the present disclosure are not chemically modified, and comprise the standard ribonucleotides consisting of adenosine, guanosine, cytosine and uridine.
  • the lipid nanoparticle comprises at least one ionizable cationic lipid , at least one non-cationic lipid, at least one sterol, and/or at least one polyethylene glycol (PEG)-modified lipid.
  • the lipid nanoparticle comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid.
  • the ionizable cationic lipid comprises the following compound:
  • ZIKV mRNA vaccines encoding a JEV signal peptide fused to prME provide sterilizing immunity in non-human primates at a 20-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
  • RNA vaccine comprising an ORF encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to induce in the subject a ZIKV prME-specific immune response, wherein the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 5-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
  • the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 10-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
  • the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 15-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
  • the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 20- fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
  • a subject may be any mammal, including non-human primate and human subjects.
  • a subject is a human subject.
  • methods of the present disclosure comprise administering to a subject a RNA vaccine comprising an ORF encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to reduce viral load in the subject by at least 80%, relative to a control (e.g., at 3-7 days following exposure to ZIKV), wherein the control is the viral load in a subject administered a ZIKV RNA vaccine lacking the JEV signal sequence.
  • the amount of ZIKV RNA vaccine administered is effective to reduce viral load in the subject by at least 85%, at least 90%, at least 95%, at least 98% or 100%.
  • the control is the viral load in a subject administered a ZIKV RNA vaccine containing an IgE signal sequence.
  • the control is the viral load in an unvaccinated subject.
  • the methods comprise administering to a subject ZIKV vaccine comprising an ORF encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to induce in the subject a ZIKV prME-specific immune response, wherein efficacy of the RNA vaccine is at least 60% relative to unvaccinated control subjects.
  • the efficacy of the ZIKV RNA vaccine may be at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 98%, relative to unvaccinated control subjects.
  • the efficacy of the RNA vaccine is at least 80% relative to unvaccinated control subjects.
  • the efficacy of the RNA vaccine is at least 95% relative to unvaccinated control subjects.
  • Vaccine efficacy may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun 1 ;201(11): 1607-10). For example, vaccine efficacy may be measured by double-blind, randomized, clinical controlled trials. Vaccine efficacy may be expressed as a proportionate reduction in disease attack rate (AR) between the unvaccinated (ARU) and vaccinated (ARV) study cohorts and can be calculated from the relative risk (RR) of disease among the vaccinated group with use of the following formulas:
  • AR disease attack rate
  • vaccine effectiveness may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun 1 ;201(11): 1607-10).
  • Vaccine effectiveness is an assessment of how a vaccine (which may have already proven to have high vaccine efficacy) reduces disease in a population. This measure can assess the net balance of benefits and adverse effects of a vaccination program, not just the vaccine itself, under natural field conditions rather than in a controlled clinical trial.
  • Vaccine effectiveness is proportional to vaccine efficacy (potency) but is also affected by how well target groups in the population are immunized, as well as by other non-vaccine-related factors that influence the 'real- world' outcomes of hospitalizations, ambulatory visits, or costs.
  • a retrospective case control analysis may be used, in which the rates of vaccination among a set of infected cases and appropriate controls are compared.
  • the effective amount of a ZIKV RNA vaccine is sufficient to produce detectable levels of ZIKV prME protein as measured in serum of the subject at 1-72 hours post administration.
  • the effective amount of a ZIKV RNA vaccine amount is sufficient to produce a 1,000-10,000 neutralization titer produced by neutralizing antibody against the ZIKV prME protein as measured in serum of the subject at 1-72 hours post administration. In some embodiments, the effective amount of a ZIKV RNA vaccine amount is sufficient to produce a 1,000-5,000 neutralization titer produced by neutralizing antibody against the ZIKV prME protein as measured in serum of the subject at 1-72 hours post administration. In some embodiments, the effective amount of a ZIKV RNA vaccine amount is sufficient to produce a 5,000-10,000 neutralization titer produced by neutralizing antibody against the ZIKV prME protein as measured in serum of the subject at 1-72 hours post administration.
  • an anti-ZIKV prME protein antibody titer produced in a subject administered a ZIKV RNA vaccine is increased by at least 1 log relative to a control, wherein the control is an anti-ZIKV prME protein antibody titer produced in a subject who has not been administered a vaccine against ZIKV.
  • an anti-ZIKV prME protein antibody titer produced in a subject administered a ZIKV RNA vaccine is increased by at least 2 log relative to the control.
  • an anti-ZIKV prME protein antibody titer produced in a subject administered a ZIKV RNA vaccine is increased by at least 5 log relative to the control.
  • an anti-ZIKV prME protein antibody titer produced in a subject administered a ZIKV RNA vaccine is increased by at least 10 log relative to the control.
  • an anti-ZIKV prME protein antibody titer produced in a subject is increased at least 2 times relative to a control, wherein the control is an anti-ZIKV prME protein antibody titer produced in a subject who has not been administered a vaccine against ZIKV.
  • an anti-ZIKV prME protein antibody titer produced in a subject is increased at least 5 times relative to a control.
  • an anti- ZIKV prME protein antibody titer produced in a subject is increased at least 10 times relative to a control.
  • the effective amount of a ZIKV RNA vaccine (e.g., mRNA vaccine), as provided herein, surprisingly may be as low as 20 ⁇ g, administered for example as a single dose or as two 10 ⁇ g doses.
  • the effective amount is 20 ⁇ g, 25 ⁇ g, 30 ⁇ g, 35 ⁇ g, 40 ⁇ ⁇ , 45 ⁇ ⁇ , 50 ⁇ ⁇ , 55 ⁇ ⁇ , 60 ⁇ ⁇ , 65 ⁇ ⁇ , 70 ⁇ ⁇ , 75 ⁇ ⁇ , 80 ⁇ ⁇ , 85 ⁇ ⁇ , 90 ⁇ ⁇ , 95 ⁇ ⁇ , 100 ⁇ ⁇ , 110 ⁇ g, 120 ⁇ g, 130 ⁇ g, 140 ⁇ g, 150 ⁇ g, 160 ⁇ g, 170 ⁇ g, 180 ⁇ g, 190 ⁇ g or 200 ⁇ g.
  • the effective amount is a total dose of 25 ⁇ g-200 ⁇ g.
  • Table 1 below provides examples of ZIKV mRNA vaccine sequences
  • ORFs open reading frames provided in Table 1 may include any of the following 5' UTR sequences or other 5' UTR sequence (e.g., wild-type 5' UTR sequence):
  • any of the ORFs provided in Table 1 may include any of the following 3'
  • UTR sequences or other 3' UTR sequence e.g., wild-type 3' UTR sequence:
  • any of the ORFs provided in Table 1 may include a polyA tail (e.g., 100 nucleotides).
  • a ZIKV mRNA vaccine (mRNA-1893) comprises the following sequence, including a 5' UTR, 3' UTR and polyA tail:
  • Non-human primates were immunized intramuscularly (IM) with a vaccine composition comprising mRNA encoding either an IgE signal peptide fused to a ZIKV prME antigen (mRNA- 1325, SEQ ID NO:X) (a single 200 ⁇ g dose, or a 10 ⁇ g, 50 ⁇ g or 200 ⁇ g dose followed by an equivalent boost at week 4, or a JEV signal peptide fused to a ZIKV prME antigen (mRNA-1893, SEQ ID NO:X) (a 10 ⁇ g followed by an equivalent boost at week 4).
  • Animals were challenged at week 8 with 1000 focus-forming units (FFU) of Zika virus. Serum was collected 3, 4, 5, 6 and 7 days post challenge.
  • FIG. 1 shows that while a single 200 ⁇ g dose of the mRNA-1325 vaccine conferred nearly complete protection, the mRNA-1893 vaccine unexpectedly provided sterilizing immunity at a 20 fold lower dose.
  • Neutralizing antibody titers (EC50 fold change relative to week 8) are shown in FIG. 2.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein are Zika virus RNA vaccines comprising an open reading frame (ORF) encoding a Japanese Encephalitis virus (JEV) signal peptide fused to a Zika virus prME protein and methods of producing an antigen-specific immune response in a subject.

Description

ZIKA VIRUS RNA VACCINES
RELATED APPLICATION
This application claims the benefit under 35 U.S.C. § 119(e) of U.S. provisional application number 62/558,746, filed September 14, 2017, which is incorporated by reference herein in its entirety.
BACKGROUND
Zika virus (ZIKV) was identified in 1947 from a sentinel Rhesus monkey in the Zika Forest of Uganda. Historically, ZIKV circulated between Aedes species mosquitoes, non- human primates in the jungle, and episodically spilled into human populations in Africa and parts of Southeast Asia. Infection was associated with a mild, self-limiting febrile illness characterized by headache, rash, conjunctivitis, myalgia, and arthralgia. Since 2010, and especially in the context of its spread and dissemination to countries of the Western
Hemisphere, more severe clinical consequences have been observed. Infection of fetuses in utero during pregnancy, particularly during the first and second trimesters, has been associated with placental insufficiency and congenital malformations including cerebral calcifications, microcephaly, and miscarriage. In adults, ZIKV infection is linked to an increased incidence of Guillain-Barre syndrome (GBS), an autoimmune disease characterized by paralysis and polyneuropathy. In addition to mosquito and in utero transmission, sexual transmission of ZIKV has been described from men-to-women, men-to-men, and women-to- men. Persistent ZIKV infection can occur, as viral RNA has been detected in semen, sperm, and vaginal secretions up to 6 months following infection. Thus, ZIKV is now a global disease with locally-acquired and travel-associated transmission through multiple routes in the Americas, Africa, and Asia. The emergence of ZIKV infection has prompted a global effort to develop safe and effective vaccines.
SUMMARY
Experimental results provided herein demonstrate an unexpected improvement in efficacy with Zika virus (ZIKV) RNA vaccines encoding a Japanese encephalitis virus (JEV) signal peptide fused to a ZIKV prME protein. As shown in the Examples, the ZIKV mRNA vaccine encoding a JEV signal peptide fused to prME unexpectedly provided sterilizing immunity in non-human primates at a 20-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
Thus, in some aspects, provided herein are RNA vaccines that comprise a 5' UTR, an ORF encoding a JEV signal peptide fused to a ZIKV prME protein, and a 3' UTR. In some embodiments, the 5' UTR is selected from SEQ ID NO: 13 and SEQ ID NO: 14. In some embodiments, the ORF comprises a sequence selected from SEQ ID NOs: l-6. In some embodiments, the 3' UTR is selected from SEQ ID NO: 15 and SEQ ID NO: 16. In some embodiments, the JEV signal peptide comprises the following sequence:
MWLVSLAIVTACAGA (SEQ ID NO: 18). In some embodiments, the JEV signal peptide is encoded by the following sequence: AUGUGGCUGGUGUCCCUGGCCAUCGUGACA GCCUGUGCUGGCGCC (SEQ ID NO: 19).
Also provided herein are methods comprising administering to a subject a RNA vaccine comprising an open reading frame (ORF) encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to induce in the subject a ZIKV prME- specific immune response, wherein the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 10-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME. In some embodiments, the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 20-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
In some aspects, the methods comprise administering to a subject a RNA vaccine comprising an ORF encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to reduce viral load in the subject by at least 80%, relative to a control, at 3- 7 days following exposure to ZIKV, wherein the control is the viral load in a subject administered a ZIKV RNA vaccine lacking the JEV signal sequence.
In other aspects, the methods comprise administering to a subject a RNA vaccine comprising an ORF encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to induce in the subject a ZIKV prME-specific immune response, wherein efficacy of the RNA vaccine is at least 80% relative to unvaccinated control subjects. BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 is a graph showing the viral yield (logio focus forming units (FFU)/ml) 3, 4, 5, 6 and 7 days post challenge (with ZIKV) in non-human primates (NHPs) vaccinated with 10 μg, 50 μg, or 200 μg ZIKV mRNA vaccine. Vaccine 'mRNA- 1325' encodes an IgE signal peptide fused to ZIKV prME. Vaccine 'mRNA-1893' encodes a JEV signal peptide fused to ZIKV prME. A single 200 μg dose of the mRNA-1325 vaccine confers nearly complete protection. Unexpectedly, the mRNA-1893 vaccine outperforms the mRNA-1325 vaccine in this model by at least 20x.
FIG. 2 includes graphs showing neutralizing antibody titers (EC50 fold change relative to week 8) obtained from the same NHP experiments described in FIG. 1.
DETAILED DESCRIPTION
Zika virus (ZIKV) is a member of the Flaviviridae virus family and the flavivirus genus. In humans, it causes a disease known as Zika fever. It is related to dengue, yellow fever, West Nile and Japanese encephalitis, viruses that are also members of the virus family Flaviviridae. ZIKV is spread to people through mosquito bites. The most common symptoms of ZIKV disease (Zika) are fever, rash, joint pain, and red eye. The illness is usually mild with symptoms lasting from several days to a week. There is no vaccine to prevent, or medicine to treat ZIKV.
Provided herein, in some embodiments, are ZIKV ribonucleic acid (RNA) vaccines (e.g., mRNA vaccines) comprising a 5' untranslated region (UTR), an open reading frame (ORF) encoding a JEV signal peptide fused to a ZIKV prME protein, and a 3' UTR. In some embodiments, the ZIKV RNA vaccines comprise a polyA tail.
A 5' UTR is region of an mRNA that is directly upstream (5') from the start codon
(the first codon of an mRNA transcript translated by a ribosome). A 5' UTR does not encode a polypeptide (is non-coding). In some embodiments, a 5' UTR of the present disclosure comprises a sequence selected from SEQ ID NO: 13 and SEQ ID NO: 14.
A 3' UTR is region of an mRNA that is directly downstream (3') from the stop codon (the codon of an mRNA transcript that signals a termination of translation) A 3' UTR does not encode a polypeptide (is non-coding). In some embodiments, a 3' UTR of the present disclosure comprises a sequence selected from SEQ ID NO: 15 and SEQ ID NO: 16.
A polyA tail is a region of mRNA that is downstream, e.g., directly downstream, from the 3' UTR and contains multiple, consecutive adenosine monophosphates. In a relevant biological setting (e.g., in cells, in vivo), the polyA tail functions to protect mRNA from enzymatic degradation, e.g., in the cytoplasm, and aids in transcription termination, export of the mRNA from the nucleus, and translation. A polyA tail may comprise, for example, 10 to 300 adenosine monophosphates. For example, a polyA tail may comprise 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290 or 300 adenosine monophosphates. In some embodiments, a polyA tail comprises 50 to 250 adenosine monophosphates. In some embodiments, a polyA tail comprises 100 adenosine monophosphates.
In some embodiments, the ZIKV RNA vaccine comprises 5' terminal cap, for example, 7mG(5')ppp(5')NlmpNp.
An open reading frame is a continuous stretch of DNA or RNA beginning with a start codon (e.g., methionine (ATG or AUG)) and ending with a stop codon (e.g., TAA, TAG or TGA, or UAA, UAG or UGA). In some embodiments, an ORF of the present disclosure is selected from SEQ ID NO: l, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6. In some embodiments, the ORF comprises the sequence of SEQ ID NO: l. In some embodiments, the ORF comprises the sequence of SEQ ID NO:2. In some embodiments, the ORF comprises the sequence of SEQ ID NO:3. In some embodiments, the ORF comprises the sequence of SEQ ID NO:4. In some embodiments, the ORF comprises the sequence of SEQ ID NO:5. In some embodiments, the ORF comprises the sequence of SEQ ID NO:6.
The ZIKV RNA vaccines (e.g., mRNA vaccines) of the present disclosure encode a JEV signal peptide (e.g., SEQ ID NO: 18) fused (in frame) to a ZIKV prME protein. The particular prME sequence may be from any ZIKV strain, for example those strains as are known in the art or as otherwise described herein, such as a Brazilian strain, a Micronesian strain, or an African strain. Within the Zika family, there is a high level of homology within the prME sequence (>90%) across all strains so far isolated. The high degree of homology is also preserved when comparing the original isolates from 1947 to the more contemporary strains circulating in Brazil in 2015, suggesting that there is "drift" occurring from the original isolates. Furthermore, attenuated virus preparations have provided cross- immunization to all other strains tested, including Latin American/Asian, and African.
Overall, this data suggests that cross-protection of all Zika strains is possible with a vaccine based on prME. In fact, the prM/M and E proteins of ZIKV have a very high level (99%) of sequence conservation between the currently circulating Asiatic and Brazilian viral strains.
The M and E proteins are on the surface of the viral particle. Neutralizing antibodies predominantly bind to the E protein, the preM/M protein functions as a chaperone for proper folding of E protein and prevent premature fusion of E protein within acidic compartments along the cellular secretory pathway. In some embodiments, the ZIKV prME protein comprises a sequence selected from SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12. In some embodiments, the ZIKV prME protein comprises the sequence of SEQ ID NO:7. In some embodiments, the ZIKV prME protein comprises the sequence of SEQ ID NO:8. In some embodiments, the ZIKV prME protein comprises the sequence of SEQ ID NO:9. In some embodiments, the ZIKV prME protein comprises the sequence of SEQ ID NO: 10. In some embodiments, the ZIKV prME protein comprises the sequence of SEQ ID NO: 11. In some embodiments, the ZIKV prME protein comprises the sequence of SEQ ID NO: 12.
ZIKV RNA vaccines (e.g., mRNA vaccines) of the present disclosure encode a JEV signal peptide fused to a prME protein. Signal peptides, comprising the N-terminal 15-60 amino acids of proteins, are typically needed for the translocation across the membrane on the secretory pathway and, thus, universally control the entry of most proteins both in eukaryotes and prokaryotes to the secretory pathway. In eukaryotes, the signal peptide of a nascent precursor protein (pre-protein) directs the ribosome to the rough endoplasmic reticulum (ER) membrane and initiates the transport of the growing peptide chain across it for processing. ER processing produces mature proteins, wherein the signal peptide is cleaved from precursor proteins, typically by a ER-resident signal peptidase of the host cell, or they remain uncleaved and function as a membrane anchor. A signal peptide may also facilitate the targeting of the protein to the cell membrane. In some embodiments, the JEV signal peptide of the present disclosure comprises the sequence of SEQ ID NO: 18.
In some embodiments, a RNA (e.g., mRNA) of a ZIKV RNA vaccine of the present disclosure is chemically modified. For example, at least 80% of the uracil in the ORF may have a chemical modification selected from Nl-methyl-pseudouridine and Nl-ethyl- pseudouridine. In some embodiments, at least 85%, at least 90%, at least 95% or 100% of the uracil in the ORF have a chemical modification. In some embodiments, the chemical modification is in the 5-position of the uracil.
In some embodiments, at least one RNA (e.g., mRNA) of the ZIKV RNA vaccines of the present disclosure are not chemically modified, and comprise the standard ribonucleotides consisting of adenosine, guanosine, cytosine and uridine.
ZIKV RNA vaccines (e.g., mRNA vaccines) of the present disclosure are typically formulated in lipid nanoparticle. In some embodiments, the lipid nanoparticle comprises at least one ionizable cationic lipid , at least one non-cationic lipid, at least one sterol, and/or at least one polyethylene glycol (PEG)-modified lipid. In some embodiments, the lipid nanoparticle comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid. In some embodiments, the ionizable cationic lipid comprises the following compound:
Figure imgf000007_0001
Data provided herein demonstrates that ZIKV mRNA vaccines encoding a JEV signal peptide fused to prME provide sterilizing immunity in non-human primates at a 20-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME. Thus, provided herein, in some embodiments, are methods comprising administering to a subject a RNA vaccine comprising an ORF encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to induce in the subject a ZIKV prME-specific immune response, wherein the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 5-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME. In some embodiments, the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 10-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME. the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 15-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME. the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 20- fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
A subject may be any mammal, including non-human primate and human subjects. Typically, a subject is a human subject.
In some embodiments, methods of the present disclosure comprise administering to a subject a RNA vaccine comprising an ORF encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to reduce viral load in the subject by at least 80%, relative to a control (e.g., at 3-7 days following exposure to ZIKV), wherein the control is the viral load in a subject administered a ZIKV RNA vaccine lacking the JEV signal sequence. In some embodiments, the amount of ZIKV RNA vaccine administered is effective to reduce viral load in the subject by at least 85%, at least 90%, at least 95%, at least 98% or 100%. In some embodiments, the control is the viral load in a subject administered a ZIKV RNA vaccine containing an IgE signal sequence. In some embodiments, the control is the viral load in an unvaccinated subject.
In some embodiments, the methods comprise administering to a subject ZIKV vaccine comprising an ORF encoding a JEV signal peptide fused to a ZIKV prME protein in an effective amount to induce in the subject a ZIKV prME-specific immune response, wherein efficacy of the RNA vaccine is at least 60% relative to unvaccinated control subjects. For example, the efficacy of the ZIKV RNA vaccine may be at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 98%, relative to unvaccinated control subjects. In some embodiments, the efficacy of the RNA vaccine is at least 80% relative to unvaccinated control subjects. In some embodiments, the efficacy of the RNA vaccine is at least 95% relative to unvaccinated control subjects.
Vaccine efficacy may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun 1 ;201(11): 1607-10). For example, vaccine efficacy may be measured by double-blind, randomized, clinical controlled trials. Vaccine efficacy may be expressed as a proportionate reduction in disease attack rate (AR) between the unvaccinated (ARU) and vaccinated (ARV) study cohorts and can be calculated from the relative risk (RR) of disease among the vaccinated group with use of the following formulas:
Efficacy = (ARU - ARV)/ARU x 100; and
Efficacy = (1-RR) x 100.
Likewise, vaccine effectiveness may be assessed using standard analyses (see, e.g., Weinberg et al., J Infect Dis. 2010 Jun 1 ;201(11): 1607-10). Vaccine effectiveness is an assessment of how a vaccine (which may have already proven to have high vaccine efficacy) reduces disease in a population. This measure can assess the net balance of benefits and adverse effects of a vaccination program, not just the vaccine itself, under natural field conditions rather than in a controlled clinical trial. Vaccine effectiveness is proportional to vaccine efficacy (potency) but is also affected by how well target groups in the population are immunized, as well as by other non-vaccine-related factors that influence the 'real- world' outcomes of hospitalizations, ambulatory visits, or costs. For example, a retrospective case control analysis may be used, in which the rates of vaccination among a set of infected cases and appropriate controls are compared. Vaccine effectiveness may be expressed as a rate difference, with use of the odds ratio (OR) for developing infection despite vaccination: Effectiveness = (1 - OR) x 100.
In some embodiments, the effective amount of a ZIKV RNA vaccine is sufficient to produce detectable levels of ZIKV prME protein as measured in serum of the subject at 1-72 hours post administration.
In some embodiments, the effective amount of a ZIKV RNA vaccine amount is sufficient to produce a 1,000-10,000 neutralization titer produced by neutralizing antibody against the ZIKV prME protein as measured in serum of the subject at 1-72 hours post administration. In some embodiments, the effective amount of a ZIKV RNA vaccine amount is sufficient to produce a 1,000-5,000 neutralization titer produced by neutralizing antibody against the ZIKV prME protein as measured in serum of the subject at 1-72 hours post administration. In some embodiments, the effective amount of a ZIKV RNA vaccine amount is sufficient to produce a 5,000-10,000 neutralization titer produced by neutralizing antibody against the ZIKV prME protein as measured in serum of the subject at 1-72 hours post administration.
In some embodiments, an anti-ZIKV prME protein antibody titer produced in a subject administered a ZIKV RNA vaccine is increased by at least 1 log relative to a control, wherein the control is an anti-ZIKV prME protein antibody titer produced in a subject who has not been administered a vaccine against ZIKV. In some embodiments, an anti-ZIKV prME protein antibody titer produced in a subject administered a ZIKV RNA vaccine is increased by at least 2 log relative to the control. In some embodiments, an anti-ZIKV prME protein antibody titer produced in a subject administered a ZIKV RNA vaccine is increased by at least 5 log relative to the control. In some embodiments, an anti-ZIKV prME protein antibody titer produced in a subject administered a ZIKV RNA vaccine is increased by at least 10 log relative to the control.
In some embodiments, an anti-ZIKV prME protein antibody titer produced in a subject is increased at least 2 times relative to a control, wherein the control is an anti-ZIKV prME protein antibody titer produced in a subject who has not been administered a vaccine against ZIKV. In some embodiments, an anti-ZIKV prME protein antibody titer produced in a subject is increased at least 5 times relative to a control. In some embodiments, an anti- ZIKV prME protein antibody titer produced in a subject is increased at least 10 times relative to a control.
The effective amount of a ZIKV RNA vaccine (e.g., mRNA vaccine), as provided herein, surprisingly may be as low as 20 μg, administered for example as a single dose or as two 10 μg doses. In some embodiments, the effective amount is 20 μg, 25 μg, 30 μg, 35 μg, 40 μβ, 45 μβ, 50 μβ, 55 μβ, 60 μβ, 65 μβ, 70 μβ, 75 μβ, 80 μβ, 85 μβ, 90 μβ, 95 μβ, 100 μβ, 110 μg, 120 μg, 130 μg, 140 μg, 150 μg, 160 μg, 170 μg, 180 μg, 190 μg or 200 μg. In some embodiments, the effective amount is a total dose of 25 μg-200 μg.
Table 1 below provides examples of ZIKV mRNA vaccine sequences and
corresponding protein sequences encoded by the vaccines.
Table 1 ZIKV mRNA Vaccine Sequences
ORF (with JEV signal sequence underlined) Protein (with JEV signal sequence underlined)
ZIKVprME Brazil Isolate (mRNA) ZIKV prME Brazil Isolate (protein)
AUGUGGCUGGUGUCCCUGGCCAUCGUGACAG MWLVSLAIVTACAGAAEVTRRGSAYYMYLDR
CCUGUGCUGGCGCCGCUGAAGUGACCAGAAG NDAGEAISFPTTLGMNKCYIQIMDLGHMCDAT
AGGCAGCGCCUACUACAUGUACCUGGACCGG MSYECPMLDEGVEPDDVDCWCNTTSTWVVYG
AACGAUGCCGGCGAGGCCAUCAGCUUUCCAA TCHHKKGEARRSRRAVTLPSHSTRKLQTRSQTW
CCACCCUGGGCAUGAACAAGUGCUACAUCCA LESREYTKHLIRVENWIFRNPGFALAAAAIAWLL
GAUCAUGGACCUGGGCCACAUGUGCGACGCC GSSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVE
ACCAUGAGCUACGAGUGCCCCAUGCUGGACG GMSGGTWVDVVLEHGGCVTVMAQDKPTVDIE
AGGGCGUGGAACCCGACGAUGUGGACUGCUG LVTTTVSNMAEVRSYCYEASISDMASDSRCPTQ
GUGCAACACCACCAGCACCUGGGUGGUGUAC GEAYLDKQSDTQYVCKRTLVDRGWGNGCGLF
GGCACCUGUCACCACAAGAAGGGCGAAGCCA GKGS LVTC AKF ACS KKMTGKSIQPENLEYRIML
GACGGUCCAGACGGGCCGUGACACUGCCUAG SVHGSQHSGMIVNDTGHETDENRAKVEITPNSP
CCACAGCACCAGAAAGCUGCAGACCCGGUCC RAEATLGGFGSLGLDCEPRTGLDFSDLYYLTMN
CAGACCUGGCUGGAAAGCAGAGAGUACACCA NKHWLVHKEWFHDIPLPWHAGADTGTPHWNN
AGCACCUGAUCCGGGUGGAAAACUGGAUCUU KEALVEFKDAHAKRQTVVVLGSQEGAVHTALA
CCGGAACCCCGGCUUUGCCCUGGCCGCUGCU GALEAEMDGAKGRLSSGHLKCRLKMDKLRLKG
GCUAUUGCUUGGCUGCUGGGCAGCAGCACCU VSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGT
CCCAGAAAGUGAUCUACCUCGUGAUGAUCCU DGPCKVPAQMAVDMQTLTPVGRLITANPVITES
GCUGAUCGCCCCUGCCUACAGCAUCCGGUGU TENSKMMLELDPPFGDSYIVIGVGEKKITHHWH
AUCGGCGUGUCCAACCGGGACUUCGUGGAAG RSGSTIGKAFEATVRGAKRMAVLGDTAWDFGS
GCAUGAGCGGCGGCACAUGGGUGGACGUGG VGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQIL
UGCUGGAACAUGGCGGCUGCGUGACAGUGA IGTLLMWLGLNTKNGSISLMCLALGGVLIFLSTA
UGGCCCAGGACAAGCCCACCGUGGACAUCGA VSA (SEQ ID NO:7)
GCUCGUGACCACCACCGUGUCCAAUAUGGCC
GAAGUGCGGAGCUACUGCUACGAGGCCAGCA
UCAGCGACAUGGCCAGCGACAGCAGAUGCCC
UACACAGGGCGAGGCCUACCUGGACAAGCAG
UCCGACACCCAGUACGUGUGCAAGCGGACCC
UGGUGGAUAGAGGCUGGGGCAAUGGCUGCG
GCCUGUUUGGCAAGGGCAGCCUCGUGACCUG
CGCCAAGUUCGCCUGCAGCAAGAAGAUGACC
GGCAAGAGCAUCCAGCCCGAGAACCUGGAAU
ACCGGAUCAUGCUGAGCGUGCACGGCAGCCA
GCACUCCGGCAUGAUCGUGAACGACACCGGC
CACGAGACAGACGAGAACCGGGCCAAGGUGG
AAAUCACCCCUAACAGCCCUAGAGCCGAGGC
CACACUGGGCGGCUUUGGAUCUCUGGGCCUG
GACUGCGAGCCUAGAACCGGCCUGGAUUUCA
GCGACCUGUACUACCUGACCAUGAACAACAA
GCACUGGCUGGUGCACAAAGAGUGGUUCCAC
GACAUCCCUCUGCCCUGGCAUGCCGGCGCUG ORF (with JEV signal sequence underlined) Protein (with JEV signal sequence underlined)
AUACAGGCACACCCCACUGGAACAACAAAGA
GGCUCUGGUGGAAUUCAAGGACGCCCACGCC
AAGCGGCAGACCGUGGUGGUGCUGGGAUCUC
AGGAAGGCGCCGUGCAUACAGCUCUGGCAGG
CGCCCUGGAAGCCGAAAUGGAUGGCGCCAAA
GGCAGACUGUCCAGCGGCCACCUGAAGUGCC
GGCUGAAGAUGGACAAGCUGCGGCUGAAGG
GCGUGUCCUACUCCCUGUGUACCGCCGCCUU
CACCUUCACCAAGAUCCCCGCCGAGACACUG
CACGGCACCGUGACUGUGGAAGUGCAGUACG
CCGGCACCGACGGCCCUUGUAAAGUGCCUGC
UCAGAUGGCCGUGGAUAUGCAGACCCUGACC
CCUGUGGGCAGACUGAUCACCGCCAACCCCG
UGAUCACCGAGAGCACCGAGAACAGCAAGAU
GAUGCUGGAACUGGACCCACCCUUCGGCGAC
AGCUACAUCGUGAUCGGCGUGGGAGAGAAG
AAGAUCACCCACCACUGGCACAGAAGCGGCA
GCACCAUCGGCAAGGCCUUUGAGGCUACAGU
GCGGGGAGCCAAGAGAAUGGCCGUGCUGGG
AGAUACCGCCUGGGACUUUGGCUCUGUGGGC
GGAGCCCUGAACUCUCUGGGCAAGGGAAUCC
ACCAGAUCUUCGGAGCCGCCUUUAAGAGCCU
GUUCGGCGGCAUGAGCUGGUUCAGCCAGAUC
CUGAUCGGCACCCUGCUGAUGUGGCUGGGCC
UGAACACCAAGAACGGCAGCAUCUCCCUGAU
GUGCCUGGCUCUGGGAGGCGUGCUGAUCUUC
CUGAGCACAGCCGUGUCUGCC (SEQ ID NO: l)
ZIKVprME Brazil Isolate (mRNA), with T76R, ZIKV prME Brazil Isolate (protein), with T76R, Q77E, W101R, L107R mutations Q77E, W101R, L107R mutations
AUGUGGCUGGUGUCCCUGGCCAUCGUGACAG MWLVSLAIVTACAGAAEVTRRGSAYYMYLDR
CCUGUGCUGGCGCCGCUGAAGUGACCAGAAG NDAGEAISFPTTLGMNKCYIQIMDLGHMCDAT
AGGCAGCGCCUACUACAUGUACCUGGACCGG MSYECPMLDEGVEPDDVDCWCNTTSTWVVYG
AACGAUGCCGGCGAGGCCAUCAGCUUUCCAA TCHHKKGEARRSRRAVTLPSHSTRKLQTRSQTW
CCACCCUGGGCAUGAACAAGUGCUACAUCCA LESREYTKHLIRVENWIFRNPGFALAAAAIAWLL
GAUCAUGGACCUGGGCCACAUGUGCGACGCC GSSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVE
ACCAUGAGCUACGAGUGCCCCAUGCUGGACG GMSGGTWVDVVLEHGGCVTVMAQDKPTVDIE
AGGGCGUGGAACCCGACGAUGUGGACUGCUG LVTTTVSNMAEVRSYCYEASISDMASDSRCPRE
GUGCAACACCACCAGCACCUGGGUGGUGUAC GEAYLDKQSDTQYVCKRTLVDRGRGNGCGRFG
GGCACCUGUCACCACAAGAAGGGCGAAGCCA KGSLVTCAKFACSKKMTGKSIQPENLEYRIMLS
GACGGUCCAGACGGGCCGUGACACUGCCUAG VHGSQHSGMIVNDTGHETDENRAKVEITPNSPR
CCACAGCACCAGAAAGCUGCAGACCCGGUCC AEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNN
CAGACCUGGCUGGAAAGCAGAGAGUACACCA KHWLVHKEWFHDIPLPWHAGADTGTPHWNNK
AGCACCUGAUCCGGGUGGAAAACUGGAUCUU EALVEFKDAHAKRQTVVVLGSQEGAVHTALAG
CCGGAACCCCGGCUUUGCCCUGGCCGCUGCU ALE AEMD G AKGRLS S GHLKCRLKMDKLRLKG V
GCUAUUGCUUGGCUGCUGGGCAGCAGCACCU SYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTD
CCCAGAAAGUGAUCUACCUCGUGAUGAUCCU GPCKVPAQMAVDMQTLTPVGRLITANPVITEST
GCUGAUCGCCCCUGCCUACAGCAUCCGGUGU ENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
AUCGGCGUGUCCAACCGGGACUUCGUGGAAG SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSV
GCAUGAGCGGCGGCACAUGGGUGGACGUGG GGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILI
UGCUGGAACAUGGCGGCUGCGUGACAGUGA GTLLMWLGLNTKNGSISLMCLALGGVLIFLSTA
UGGCCCAGGACAAGCCCACCGUGGACAUCGA VSA (SEQ ID NO:8)
GCUCGUGACCACCACCGUGUCCAAUAUGGCC
GAAGUGCGGAGCUACUGCUACGAGGCCAGCA
UCAGCGACAUGGCCAGCGACAGCAGAUGCCC
CAGAGAGGGCGAGGCCUACCUGGACAAGCAG
UCCGACACCCAGUACGUGUGCAAGCGGACCC
UGGUGGACAGAGGCAGAGGCAAUGGCUGCG ORF (with JEV signal sequence underlined) Protein (with JEV signal sequence underlined)
GCAGAUUCGGCAAGGGCAGCCUCGUGACCUG
CGCCAAGUUCGCCUGCAGCAAGAAGAUGACC
GGCAAGAGCAUCCAGCCCGAGAACCUGGAAU
ACCGGAUCAUGCUGAGCGUGCACGGCAGCCA
GCACUCCGGCAUGAUCGUGAACGACACCGGC
CACGAGACAGACGAGAACCGGGCCAAGGUGG
AAAUCACCCCUAACAGCCCUAGAGCCGAGGC
CACACUGGGCGGCUUUGGAUCUCUGGGCCUG
GACUGCGAGCCUAGAACCGGCCUGGAUUUCA
GCGACCUGUACUACCUGACCAUGAACAACAA
GCACUGGCUGGUGCACAAAGAGUGGUUCCAC
GACAUCCCUCUGCCCUGGCAUGCCGGCGCUG
AUACAGGCACACCCCACUGGAACAACAAAGA
GGCUCUGGUGGAAUUCAAGGACGCCCACGCC
AAGCGGCAGACCGUGGUGGUGCUGGGAUCUC
AGGAAGGCGCCGUGCAUACAGCUCUGGCAGG
CGCCCUGGAAGCCGAAAUGGAUGGCGCCAAA
GGCAGACUGUCCAGCGGCCACCUGAAGUGCC
GGCUGAAGAUGGACAAGCUGCGGCUGAAGG
GCGUGUCCUACUCCCUGUGUACCGCCGCCUU
CACCUUCACCAAGAUCCCCGCCGAGACACUG
CACGGCACCGUGACUGUGGAAGUGCAGUACG
CCGGCACCGACGGCCCUUGUAAAGUGCCUGC
UCAGAUGGCCGUGGAUAUGCAGACCCUGACC
CCUGUGGGCAGACUGAUCACCGCCAACCCCG
UGAUCACCGAGAGCACCGAGAACAGCAAGAU
GAUGCUGGAACUGGACCCACCCUUCGGCGAC
AGCUACAUCGUGAUCGGCGUGGGAGAGAAG
AAGAUCACCCACCACUGGCACAGAAGCGGCA
GCACCAUCGGCAAGGCCUUUGAGGCUACAGU
GCGGGGAGCCAAGAGAAUGGCCGUGCUGGG
AGAUACCGCCUGGGACUUUGGCUCUGUGGGC
GGAGCCCUGAACUCUCUGGGCAAGGGAAUCC
ACCAGAUCUUCGGAGCCGCCUUUAAGAGCCU
GUUCGGCGGCAUGAGCUGGUUCAGCCAGAUC
CUGAUCGGCACCCUGCUGAUGUGGCUGGGCC
UGAACACCAAGAACGGCAGCAUCUCCCUGAU
GUGCCUGGCUCUGGGAGGCGUGCUGAUCUUC
CUGAGCACAGCCGUGUCUGCC (SEQ ID NO:2)
ZIKVprME Micronesia Isolate (mRNA) ZIKV prME Micronesia Isolate (protein)
AUGUGGCUGGUGAGCCUGGCCAUCGUGACCG MWLVSLAIVTACAGAVEVTRRGSAYYMYLDRS
CCUGCGCCGGCGCCGUGGAGGUGACCAGAAG DAGEAISFPTTLGMNKCYIQIMDLGHMCDATMS
AGGCAGCGCCUACUACAUGUACCUGGACAGA YECPMLDEGVEPDDVDCWCNTTSTWVVYGTC
AGCGACGCCGGCGAGGCCAUCAGCUUCCCUA HHKKGE ARRS RR A VTLP S HS TRKLQTRS QT WLE
CCACCCUGGGCAUGAACAAGUGCUACAUCCA SREYTKHLIRVENWIFRNPGFALAAAAIAWLLG
GAUCAUGGACCUGGGCCACAUGUGCGACGCC SSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEG
ACCAUGAGCUACGAGUGCCCUAUGCUGGACG MSGGTWVDVVLEHGGCVTVMAQDKPAVDIEL
AGGGCGUGGAGCCUGACGACGUGGACUGCUG VTTTVSNMAEVRSYCYEASISDMASDSRCPTQG
GUGCAACACCACCAGCACCUGGGUGGUGUAC EAYLDKQSDTQYVCKRTLVDRGWGNGCGLFG
GGCACCUGCCACCACAAGAAGGGAGAGGCGA KGSLVTCAKFACSKKMTGKSIQPENLEYRIMLS
GAAGAAGCAGGAGAGCCGUGACCCUGCCUAG VHGSQHSGMIVNDTGHETDENRAKVEITPNSPR
CCACAGCACCAGAAAGCUGCAGACCCGGAGC AEATLGGFGSLGLDCEPRTGLDFSDLYYLTMNN
CAGACCUGGCUGGAGAGCAGAGAGUACACCA KHWLVHKEWFHDIPLPWHAGADTGTPHWNNK
AGCACCUGAUCAGAGUGGAGAACUGGAUCU EALVEFKDAHAKRQTVVVLGSQEGAVHTALAG
UCAGAAACCCUGGCUUCGCCCUGGCCGCGGC ALE AEMD G AKGRLS S GHLKCRLKMDKLRLKG V
UGCUAUCGCCUGGCUGCUGGGUAGUUCAACC SYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTD ORF (with JEV signal sequence underlined) Protein (with JEV signal sequence underlined)
AGCCAGAAGGUGAUCUACCUGGUGAUGAUCC GPCKVPAQMAVDMQTLTPVGRLITANPVITEST
UGCUGAUCGCCCCGGCAUACAGCAUCCGCUG ENSKMMLELDPPFGDSYIVIGVGEKKITHHWHR
CAUCGGCGUGAGCAACAGAGACUUCGUGGAG SGSTIGKAFEATVRGAKRMAVLGDTAWDFGSV
GGCAUGAGCGGAGGAACGUGGGUUGACGUG GGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILI
GUGCUGGAGCACGGCGGCUGCGUGACCGUGA GTLLVWLGLNTKNGSISLTCLALGGVLIFLSTAV
UGGCCCAGGACAAGCCUGCCGUGGACAUCGA SA (SEQ ID NO:9)
GCUGGUGACCACCACCGUAUCCAACAUGGCC
GAGGUGAGAAGCUACUGCUACGAGGCUAGC
AUAAGCGACAUGGCCAGCGACAGCCGAUGCC
CUACCCAGGGAGAAGCCUACCUGGACAAGCA
GAGCGACACCCAGUACGUGUGCAAGAGAACC
CUGGUGGACAGAGGCUGGGGCAACGGCUGCG
GCCUGUUCGGCAAGGGCAGCCUGGUUACUUG
CGCCAAGUUCGCCUGCAGCAAGAAGAUGACC
GGCAAGAGCAUCCAGCCUGAGAACCUGGAGU
ACAGAAUCAUGCUGAGCGUGCACGGCAGCCA
GCACAGCGGCAUGAUCGUGAACGACACCGGC
CACGAAACAGACGAGAACAGAGCCAAGGUGG
AGAUCACCCCUAACAGCCCUAGAGCCGAGGC
CACCCUUGGCGGCUUCGGCAGCCUCGGCCUG
GACUGCGAGCCUAGAACGGGCCUGGAUUUCA
GCGACCUGUACUACCUGACUAUGAAUAACAA
GCACUGGCUUGUUCACAAGGAGUGGUUCCAC
GACAUCCCUCUGCCUUGGCACGCGGGAGCUG
ACACAGGAACCCCUCACUGGAACAACAAGGA
GGCCCUAGUUGAGUUCAAGGACGCCCACGCC
AAGAGACAGACCGUGGUCGUGCUGGGUUCCC
AAGAGGGCGCUGUCCACACUGCACUCGCUGG
CGCCCUGGAGGCCGAGAUGGACGGCGCCAAG
GGAAGACUGAGCAGCGGCCACCUGAAGUGCA
GGCUGAAGAUGGACAAGCUGCGGCUGAAGG
GCGUGUCCUACAGCCUGUGCACCGCCGCCUU
CACCUUCACCAAGAUCCCUGCCGAGACACUA
CACGGCACAGUGACCGUCGAGGUGCAGUACG
CCGGCACCGACGGCCCUUGCAAGGUGCCUGC
CCAGAUGGCCGUCGAUAUGCAAACUCUGACC
CCUGUGGGACGGCUUAUCACCGCCAACCCUG
UGAUUACUGAGAGCACCGAGAAUAGCAAGA
UGAUGUUGGAACUGGACCCUCCUUUCGGCGA
CAGCUACAUCGUGAUUGGAGUUGGAGAGAA
GAAGAUCACACACCACUGGCACAGAUCUGGA
UCUACUAUUGGCAAGGCCUUCGAGGCAACAG
UGAGAGGAGCAAAGAGAAUGGCAGUUCUGG
GAGACACCGCCUGGGAUUUCGGAAGCGUAGG
AGGUGCAUUGAACUCCCUAGGAAAGGGAAU
CCACCAGAUCUUCGGAGCUGCAUUCAAGAGC
CUAUUCGGCGGAAUGUCCUGGUUCAGCCAGA
UCCUGAUCGGCACCCUGCUUGUGUGGCUUGG
AUUGAACACCAAGAACGGUAGUAUUAGUCU
GACCUGCCUGGCUCUCGGCGGUGUGCUGAUC
UUCCUGAGUACUGCGGUGAGCGCC (SEQ ID
NO:3)
ZIKVprME Micronesia Isolate (mRNA), with T76R, ZIKV prME Micronesia Isolate (protein), with T76R, Q77E, W101R, L107R mutations Q77E, W101R, L107R mutations
AUGUGGCUGGUGAGCCUGGCCAUCGUGACCG MWLVSLAIVTACAGAVEVTRRGSAYYMYLDRS CCUGCGCCGGCGCCGUGGAGGUGACCAGAAG DAGEAISFPTTLGMNKCYIQIMDLGHMCDATMS AGGCAGCGCCUACUACAUGUACCUGGACAGA YECPMLDEGVEPDDVDCWCNTTSTWVVYGTC ORF (with JEV signal sequence underlined) Protein (with JEV signal sequence underlined)
AGCGACGCCGGCGAGGCCAUCAGCUUCCCUA HHKKGE ARRS RR A VTLP S HS TRKLQTRS QT WLE
CCACCCUGGGCAUGAACAAGUGCUACAUCCA SREYTKHLIRVENWIFRNPGFALAAAAIAWLLG
GAUCAUGGACCUGGGCCACAUGUGCGACGCC SSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEG
ACCAUGAGCUACGAGUGCCCUAUGCUGGACG MSGGTWVDVVLEHGGCVTVMAQDKPAVDIEL
AGGGCGUGGAGCCUGACGACGUGGACUGCUG VTTTVSNMAEVRSYCYEASISDMASDSRCPREG
GUGCAACACCACCAGCACCUGGGUGGUGUAC EAYLDKQSDTQYVCKRTLVDRGRGNGCGRFGK
GGCACCUGCCACCACAAGAAGGGCGAGGCCA GSLVTCAKFACSKKMTGKSIQPENLEYRIMLSV
GAAGAAGCAGAAGAGCCGUGACCCUGCCUAG HGSQHSGMIVNDTGHETDENRAKVEITPNSPRA
CCACAGCACCAGAAAGCUGCAGACCAGAAGC EATLGGFGSLGLDCEPRTGLDFSDLYYLTMNNK
CAGACCUGGCUGGAGAGCAGAGAGUACACCA HWLVHKEWFHDIPLPWHAGADTGTPHWNNKE
AGCACCUGAUCAGAGUGGAGAACUGGAUCU ALVEFKDAHAKRQTVVVLGSQEGAVHTALAGA
UCAGAAACCCUGGCUUCGCCCUGGCCGCCGC LEAEMDGAKGRLSSGHLKCRLKMDKLRLKGVS
CGCCAUCGCCUGGCUGCUGGGCAGCAGCACC YSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDG
AGCCAGAAGGUGAUCUACCUGGUGAUGAUCC PCKVPAQMAVDMQTLTPVGRLITANPVITESTE
UGCUGAUCGCCCCUGCCUACAGCAUCAGAUG NSKMMLELDPPFGDSYIVIGVGEKKITHHWHRS
CAUCGGCGUGAGCAACAGAGACUUCGUGGAG GSTIGKAFEATVRGAKRMAVLGDTAWDFGSVG
GGCAUGAGCGGCGGCACCUGGGUGGACGUGG GALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIG
UGCUGGAGCACGGCGGCUGCGUGACCGUGAU TLLVWLGLNTKNGSISLTCLALGGVLIFLSTAVS
GGCCCAGGACAAGCCUGCCGUGGACAUCGAG A (SEQ ID NO: 10)
CUGGUGACCACCACCGUGAGCAACAUGGCCG
AGGUGAGAAGCUACUGCUACGAGGCCAGCAU
CAGCGACAUGGCCAGCGACAGCAGAUGCCCU
AGAGAGGGCGAGGCCUACCUGGACAAGCAGA
GCGACACCCAGUACGUGUGCAAGAGAACCCU
GGUGGACAGAGGCAGAGGCAACGGCUGCGGC
AGAUUCGGCAAGGGCAGCCUGGUGACCUGCG
CCAAGUUCGCCUGCAGCAAGAAGAUGACCGG
CAAGAGCAUCCAGCCUGAGAACCUGGAGUAC
AGAAUCAUGCUGAGCGUGCACGGCAGCCAGC
ACAGCGGCAUGAUCGUGAACGACACCGGCCA
CGAGACCGACGAGAACAGAGCCAAGGUGGAG
AUCACCCCUAACAGCCCUAGAGCCGAGGCCA
CCCUGGGCGGCUUCGGCAGCCUGGGCCUGGA
CUGCGAGCCUAGAACCGGCCUGGACUUCAGC
GACCUGUACUACCUGACCAUGAACAACAAGC
ACUGGCUGGUGCACAAGGAGUGGUUCCACGA
CAUCCCUCUGCCUUGGCACGCCGGCGCCGAC
ACCGGCACCCCUCACUGGAACAACAAGGAGG
CCCUGGUGGAGUUCAAGGACGCCCACGCCAA
GAGACAGACCGUGGUGGUGCUGGGCAGCCAG
GAGGGCGCCGUGCACACCGCCCUGGCCGGCG
CCCUGGAGGCCGAGAUGGACGGCGCCAAGGG
CAGACUGAGCAGCGGCCACCUGAAGUGCAGA
CUGAAGAUGGACAAGCUGAGACUGAAGGGC
GUGAGCUACAGCCUGUGCACCGCCGCCUUCA
CCUUCACCAAGAUCCCUGCCGAGACCCUGCA
CGGCACCGUGACCGUGGAGGUGCAGUACGCC
GGCACCGACGGCCCUUGCAAGGUGCCUGCCC
AGAUGGCCGUGGACAUGCAGACCCUGACCCC
UGUGGGCAGACUGAUCACCGCCAACCCUGUG
AUCACCGAGAGCACCGAGAACAGCAAGAUGA
UGCUGGAGCUGGACCCUCCUUUCGGCGACAG
CUACAUCGUGAUCGGCGUGGGCGAGAAGAA
GAUCACCCACCACUGGCACAGAAGCGGCAGC
ACCAUCGGCAAGGCCUUCGAGGCCACCGUGA
GAGGCGCCAAGAGAAUGGCCGUGCUGGGCGA
CACCGCCUGGGACUUCGGCAGCGUGGGCGGC
GCCCUGAACAGCCUGGGCAAGGGCAUCCACC ORF (with JEV signal sequence underlined) Protein (with JEV signal sequence underlined)
AGAUCUUCGGCGCCGCCUUCAAGAGCCUGUU CGGCGGCAUGAGCUGGUUCAGCCAGAUCCUG AUCGGCACCCUGCUGGUGUGGCUGGGCCUGA ACACCAAGAACGGCAGCAUCAGCCUGACCUG CCUGGCCCUGGGCGGCGUGCUGAUCUUCCUG AGCACCGCCGUGAGCGCC (SEQ ID NO:4)
ZIKV prME Africa Isolate (mRNA) ZIKV prME Africa Isolate (protein)
AUGUGGCUGGUGAGCCUGGCCAUCGUGACAG MWLVSLAIVTACAGAAEITRRGSAYYMYLDRS
CGUGCGCUGGAGCCGCCGAGAUCACCAGAAG DAGKAISFATTLGVNKCHVQIMDLGHMCDATM
AGGCAGCGCCUACUACAUGUACCUGGACAGA SYECPMLDEGVEPDDVDCWCNTTSTWVVYGTC
AGCGACGCCGGCAAGGCCAUCAGCUUCGCCA HHKKGE ARRS RR A VTLP S HS TRKLQTRS QT WLE
CCACCCUGGGCGUGAACAAGUGCCACGUGCA SREYTKHLIKVENWIFRNPGFALVAVAIAWLLG
GAUCAUGGACCUGGGCCACAUGUGCGACGCC SSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEG
ACCAUGAGCUACGAGUGCCCUAUGCUGGACG MSGGTWVDVVLEHGGCVTVMAQDKPTVDIEL
AGGGCGUGGAGCCUGACGACGUGGACUGCUG VTTTVSNMAEVRSYCYEASISDMASDSRCPTQG
GUGCAACACCACCAGCACCUGGGUGGUGUAC EAYLDKQSDTQYVCKRTLVDRGWGNGCGLFG
GGCACCUGCCACCACAAGAAGGGCGAGGCCA KGSLVTCAKFTCSKKMTGKSIQPENLEYRIMLS
GAAGAAGCAGACGUGCCGUGACCCUGCCUAG VHGSQHSGMIGYETDEDRAKVEVTPNSPRAEAT
CCACAGCACCAGAAAGCUGCAGACCAGAAGC LGGFGSLGLDCEPRTGLDFSDLYYLTMNNKHW
CAGACCUGGCUGGAGAGCAGAGAGUACACCA LVHKEWFHDIPLPWHAGADTGTPHWNNKEALV
AGCACCUGAUCAAGGUGGAGAACUGGAUCU EFKDAHAKRQTVVVLGSQEGAVHTALAGALEA
UCAGAAACCCUGGCUUCGCCCUGGUGGCCGU EMDGAKGRLFSGHLKCRLKMDKLRLKGVSYSL
GGCAAUUGCCUGGCUGCUGGGCAGCUCCACA CTAAFTFTKVPAETLHGTVTVEVQYAGTDGPCK
AGCCAGAAGGUGAUCUACCUGGUGAUGAUCC IPVQMAVDMQTLTPVGRLITANPVITESTENSKM
UGCUGAUCGCUCCAGCCUACAGCAUCCGAUG MLELDPPFGDSYIVIGVGDKKITHHWHRSGSTIG
CAUCGGCGUGAGCAACAGAGACUUCGUGGAG KAFEATVRGAKRMAVLGDTAWDFGSVGGVFN
GGCAUGAGCGGCGGAACCUGGGUUGACGUG SLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLV
GUGCUGGAGCACGGCGGCUGCGUGACCGUGA WLGLNTKNGSISLTCLALGGVMIFLSTAVSA
UGGCCCAGGACAAGCCUACCGUGGACAUCGA (SEQ ID NO: l l)
GCUGGUGACCACCACCGUUAGCAACAUGGCC
GAGGUGAGAAGCUACUGCUACGAGGCAUCCA
UCAGCGACAUGGCCAGCGACAGCCGCUGCCC
UACCCAGGGCGAAGCAUACCUCGAUAAGCAG
AGCGACACCCAGUACGUGUGCAAGAGAACUC
UCGUGGACAGAGGCUGGGGCAACGGCUGCGG
CCUGUUCGGCAAGGGCAGCCUGGUGACUUGC
GCCAAGUUCACCUGCAGCAAGAAGAUGACCG
GCAAGAGCAUCCAGCCUGAGAACCUGGAGUA
CAGAAUCAUGCUGAGCGUGCACGGCAGCCAG
CACAGCGGCAUGAUCGGCUACGAAACUGACG
AGGACAGAGCCAAGGUCGAAGUGACCCCUAA
CAGCCCUAGAGCCGAGGCCACCCUUGGAGGC
UUCGGCUCCCUCGGCCUGGACUGCGAGCCUA
GAACAGGACUCGACUUCAGCGACCUGUACUA
CCUGACCAUGAACAACAAGCACUGGCUGGUC
CACAAGGAGUGGUUCCACGACAUCCCUCUGC
CUUGGCACGCCGGAGCAGACACCGGCACCCC
UCACUGGAAUAACAAGGAGGCGCUUGUGGA
GUUCAAGGACGCCCACGCCAAGAGACAGACC
GUGGUUGUGCUCGGAAGUCAGGAGGGCGCC
GUGCACACCGCCCUGGCCGGAGCCCUGGAGG
CCGAGAUGGACGGCGCAAAGGGCAGACUGUU
CAGCGGCCACCUGAAGUGCAGACUGAAGAUG
GACAAGCUGAGACUUAAGGGCGUCAGCUACA
GCCUGUGCACCGCCGCCUUCACCUUCACCAA
GGUGCCUGCCGAAACCCUGCACGGAACUGUA
ACCGUAGAGGUCCAGUACGCAGGAACCGACG ORF (with JEV signal sequence underlined) Protein (with JEV signal sequence underlined)
GCCCUUGCAAGAUCCCUGUGCAGAUGGCGGU
GGAUAUGCAGACCCUGACCCCUGUUGGCCGU
UUGAUCACCGCCAACCCUGUGAUAACCGAGA
GCACCGAGAACAGCAAGAUGAUGCUGGAACU
GGACCCUCCUUUCGGCGACAGCUACAUCGUG
AUCGGAGUGGGCGAUAAGAAGAUCACCCACC
ACUGGCAUCGCAGCGGUUCUACCAUCGGAAA
GGCCUUCGAAGCUACCGUUAGAGGUGCAAAG
CGCAUGGCAGUCUUAGGUGACACCGCCUGGG
ACUUCGGUUCUGUCGGAGGCGUGUUCAACAG
UCUGGGCAAGGGAAUCCACCAGAUCUUCGGC
GCUGCCUUCAAGUCUUUGUUCGGAGGUAUG
UCUUGGUUCAGCCAGAUCCUGAUCGGCACCC
UUCUGGUUUGGCUGGGCCUCAACACCAAGAA
CGGAUCCAUAUCCCUGACCUGCCUGGCCUUG
GGCGGUGUCAUGAUCUUCCUGUCGACUGCCG
UGAGCGCC (SEQ ID NO:5)
ZIKV prME Africa Isolate (mRNA), with T76R, ZIKV prME Africa Isolate (protein), with T76R, Q77E, W101R, L107R mutations Q77E, W101R, L107R mutations
AUGUGGCUGGUGAGCCUGGCCAUCGUGACUG MWLVSLAIVTACAGAAEITRRGSAYYMYLDRS
CUUGCGCGGGUGCCGCCGAGAUCACCAGAAG DAGKAISFATTLGVNKCHVQIMDLGHMCDATM
AGGCAGCGCCUACUACAUGUACCUGGACAGA SYECPMLDEGVEPDDVDCWCNTTSTWVVYGTC
AGCGACGCCGGCAAGGCCAUCAGCUUCGCCA HHKKGE ARRS RR A VTLP S HS TRKLQTRS QT WLE
CCACCCUGGGCGUGAACAAGUGCCACGUGCA SREYTKHLIKVENWIFRNPGFALVAVAIAWLLG
GAUCAUGGACCUGGGCCACAUGUGCGACGCC SSTSQKVIYLVMILLIAPAYSIRCIGVSNRDFVEG
ACCAUGAGCUACGAGUGCCCUAUGCUGGACG MSGGTWVDVVLEHGGCVTVMAQDKPTVDIEL
AGGGCGUGGAGCCUGACGACGUGGACUGCUG VTTTVSNMAEVRSYCYEASISDMASDSRCPREG
GUGCAACACCACCAGCACCUGGGUGGUGUAC EAYLDKQSDTQYVCKRTLVDRGRGNGCGRFGK
GGCACCUGCCACCACAAGAAGGGCGAGGCCA GS L VTC AKFTC S KKMTGKS IQPENLE YRIMLS V
GAAGAAGCAGGAGGGCCGUGACCCUGCCUAG HGSQHSGMIGYETDEDRAKVEVTPNSPRAEATL
CCACAGCACCAGAAAGCUGCAGACCAGAAGC GGFGS LGLDCEPRTGLDFS DLY YLTMNNKH WL
CAGACCUGGCUGGAGAGCAGAGAGUACACCA VHKEWFHDIPLPWHAGADTGTPHWNNKEALVE
AGCACCUGAUCAAGGUGGAGAACUGGAUCU FKDAHAKRQTVVVLGSQEGAVHTALAGALEAE
UCAGAAACCCUGGCUUCGCCCUGGUGGCCGU MDGAKGRLFSGHLKCRLKMDKLRLKGVSYSLC
GGCUAUAGCCUGGCUGCUGGGAUCUUCAACA TAAFTFTKVPAETLHGTVTVEVQYAGTDGPCKI
AGCCAGAAGGUGAUCUACCUGGUGAUGAUCC PVQMAVDMQTLTPVGRLITANPVITESTENSKM
UGCUGAUCGCGCCAGCCUACAGCAUCCGCUG MLELDPPFGDSYIVIGVGDKKITHHWHRSGSTIG
CAUCGGCGUGAGCAACAGAGACUUCGUGGAG KAFEATVRGAKRMAVLGDTAWDFGSVGGVFN
GGCAUGAGCGGCGGAACUUGGGUGGACGUG SLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLV
GUGCUGGAGCACGGCGGCUGCGUGACCGUGA WLGLNTKNGSISLTCLALGGVMIFLSTAVSA
UGGCCCAGGACAAGCCUACCGUGGACAUCGA (SEQ ID NO: 12)
GCUGGUGACCACCACGGUUUCUAAUAUGGCC
GAGGUGAGAAGCUACUGCUACGAGGCAUCCA
UCAGCGACAUGGCCAGCGACAGCAGGUGCCC
UAGAGAAGGAGAAGCCUAUCUCGACAAGCA
GAGCGACACCCAGUACGUGUGCAAGAGAACC
CUCGUGGACAGAGGCAGAGGCAACGGCUGCG
GCAGAUUCGGCAAGGGCAGCCUGGUUACGUG
CGCCAAGUUCACCUGCAGCAAGAAGAUGACC
GGCAAGAGCAUCCAGCCUGAGAACCUGGAGU
ACAGAAUCAUGCUGAGCGUGCACGGCAGCCA
GCACAGCGGCAUGAUCGGCUACGAGACAGAC
GAGGACAGAGCUAAGGUCGAGGUGACCCCUA
ACUCCCCACGCGCCGAGGCUACGCUGGGAGG
CUUCGGAUCUCUGGGCCUGGACUGCGAGCCU
AGAACCGGCUUGGAUUUCAGCGACCUGUACU ORF (with JEV signal sequence underlined) Protein (with JEV signal sequence underlined)
ACCUGACCAUGAACAACAAGCACUGGUUGGU
CCACAAGGAGUGGUUCCACGACAUCCCUCUG
CCUUGGCACGCGGGCGCUGACACCGGCACCC
CUCACUGGAAUAACAAGGAGGCCUUGGUGG
AGUUCAAGGACGCCCACGCCAAGAGACAGAC
CGUGGUGGUCUUGGGUUCCCAGGAGGGCGCC
GUGCACACCGCCCUGGCAGGAGCUCUGGAGG
CCGAGAUGGACGGCGCCAAGGGUAGACUGUU
CAGCGGCCACCUGAAGUGCAGACUGAAGAUG
GAUAAGCUGAGACUCAAGGGUGUGUCAUAC
AGCCUGUGCACCGCCGCCUUCACCUUCACCA
AGGUGCCUGCCGAAACCCUGCACGGAACCGU
GACUGUAGAGGUACAGUACGCUGGCACCGAC
GGCCCUUGCAAGAUCCCUGUGCAGAUGGCCG
UUGACAUGCAGACCCUGACCCCUGUGGGCAG
GCUGAUCACCGCCAACCCUGUGAUCACUGAG
AGCACCGAGAACAGCAAGAUGAUGCUGGAAC
UGGACCCUCCUUUCGGCGACAGCUACAUCGU
GAUAGGCGUGGGCGAUAAGAAGAUCACCCAC
CAUUGGCACAGAAGUGGUUCGACUAUCGGU
AAGGCAUUCGAAGCUACAGUGAGAGGAGCC
AAGAGGAUGGCAGUGCUGGGUGACACCGCCU
GGGAUUUCGGUUCAGUGGGCGGCGUGUUCA
AUUCCCUGGGCAAGGGUAUCCACCAGAUCUU
CGGCGCUGCCUUCAAGAGCCUGUUCGGUGGA
AUGAGCUGGUUCAGCCAGAUCCUGAUCGGCA
CCCUCCUGGUUUGGCUUGGUUUGAACACCAA
GAACGGCUCUAUUUCCCUGACCUGCCUGGCA
CUAGGAGGCGUCAUGAUAUUCCUGAGUACCG
CCGUGAGCGCC (SEQ ID NO:6)
Any of the open reading frames (ORFs) provided in Table 1 may include any of the following 5' UTR sequences or other 5' UTR sequence (e.g., wild-type 5' UTR sequence):
• GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGACCCCGGCG CCGCCACC (SEQ ID NO:13)
• GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGAGCCACC (SEQ ID NO: 14). Likewise, any of the ORFs provided in Table 1 may include any of the following 3'
UTR sequences or other 3' UTR sequence (e.g., wild-type 3' UTR sequence):
• UGAUAAUAGGCUGGAGCCUCGGUGGCCUAGCUUCUUGCCCCUUGGGCCUCC CCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAA AGUCUGAGUGGGCGGC (SEQ ID NO: 15)
• UGAUAAUAGGCUGGAGCCUCGGUGGCCAUGCUUCUUGCCCCUUGGGCCUCC CCCCAGCCCCUCCUCCCCUUCCUGCACCCGUACCCCCGUGGUCUUUGAAUAA AGUCUGAGUGGGCGGC (SEQ ID NO: 16)
Further, any of the ORFs provided in Table 1 may include a polyA tail (e.g., 100 nucleotides). In some embodiments, a ZIKV mRNA vaccine (mRNA-1893) comprises the following sequence, including a 5' UTR, 3' UTR and polyA tail:
GGGAAAUAAGAGAGAAAAGAAGAGUAAGAAGAAAUAUAAGACCCCGGCGCCGCCACC AUGUGGCUGGUGUCCCUGGCCAUCGUGACAGCCUGUGCUGGCGCCGCUGAAGUGACCA GAAGAGGCAGCGCCUACUACAUGUACCUGGACCGGAACGAUGCCGGCGAGGCCAUCAG CUUUCCAACCACCCUGGGCAUGAACAAGUGCUACAUCCAGAUCAUGGACCUGGGCCAC AUGUGCGACGCCACCAUGAGCUACGAGUGCCCCAUGCUGGACGAGGGCGUGGAACCCG ACGAUGUGGACUGCUGGUGCAACACCACCAGCACCUGGGUGGUGUACGGCACCUGUCA CC AC A AGA AGGGCGA AGCC AGACGGUCC AGACGGGCCGUGAC ACUGCCU AGCC AC AGC ACCAGAAAGCUGCAGACCCGGUCCCAGACCUGGCUGGAAAGCAGAGAGUACACCAAGC ACCUGAUCCGGGUGGAAAACUGGAUCUUCCGGAACCCCGGCUUUGCCCUGGCCGCUGC UGCUAUUGCUUGGCUGCUGGGCAGCAGCACCUCCCAGAAAGUGAUCUACCUCGUGAUG AUCCUGCUGAUCGCCCCUGCCUACAGCAUCCGGUGUAUCGGCGUGUCCAACCGGGACU UCGUGGA AGGCAUGAGCGGCGGC AC AUGGGUGGACGUGGUGCUGGAAC AUGGCGGCU GCGUGACAGUGAUGGCCCAGGACAAGCCCACCGUGGACAUCGAGCUCGUGACCACCAC CGUGUCCAAUAUGGCCGAAGUGCGGAGCUACUGCUACGAGGCCAGCAUCAGCGACAUG GCCAGCGACAGCAGAUGCCCUACACAGGGCGAGGCCUACCUGGACAAGCAGUCCGACA CCCAGUACGUGUGCAAGCGGACCCUGGUGGAUAGAGGCUGGGGCAAUGGCUGCGGCC UGUUUGGCAAGGGCAGCCUCGUGACCUGCGCCAAGUUCGCCUGCAGCAAGAAGAUGAC CGGCAAGAGCAUCCAGCCCGAGAACCUGGAAUACCGGAUCAUGCUGAGCGUGCACGGC AGCCAGCACUCCGGCAUGAUCGUGAACGACACCGGCCACGAGACAGACGAGAACCGGG CCAAGGUGGAAAUCACCCCUAACAGCCCUAGAGCCGAGGCCACACUGGGCGGCUUUGG AUCUCUGGGCCUGGACUGCGAGCCUAGAACCGGCCUGGAUUUCAGCGACCUGUACUAC CUGACCAUGAACAACAAGCACUGGCUGGUGCACAAAGAGUGGUUCCACGACAUCCCUC UGCCCUGGCAUGCCGGCGCUGAUACAGGCACACCCCACUGGAACAACAAAGAGGCUCU GGUGGAAUUCAAGGACGCCCACGCCAAGCGGCAGACCGUGGUGGUGCUGGGAUCUCA GGAAGGCGCCGUGCAUACAGCUCUGGCAGGCGCCCUGGAAGCCGAAAUGGAUGGCGCC AAAGGCAGACUGUCCAGCGGCCACCUGAAGUGCCGGCUGAAGAUGGACAAGCUGCGGC UGAAGGGCGUGUCCUACUCCCUGUGUACCGCCGCCUUCACCUUCACCAAGAUCCCCGC CGAGACACUGCACGGCACCGUGACUGUGGAAGUGCAGUACGCCGGCACCGACGGCCCU UGUAAAGUGCCUGCUCAGAUGGCCGUGGAUAUGCAGACCCUGACCCCUGUGGGCAGAC UGAUCACCGCCAACCCCGUGAUCACCGAGAGCACCGAGAACAGCAAGAUGAUGCUGGA ACUGGACCCACCCUUCGGCGACAGCUACAUCGUGAUCGGCGUGGGAGAGAAGAAGAUC ACCC ACC ACUGGC AC AGA AGCGGC AGC ACC AUCGGC A AGGCCUUUG AGGCU AC AGUGC GGGGAGCCAAGAGAAUGGCCGUGCUGGGAGAUACCGCCUGGGACUUUGGCUCUGUGG GCGGAGCCCUGAACUCUCUGGGCAAGGGAAUCCACCAGAUCUUCGGAGCCGCCUUUAA GAGCCUGUUCGGCGGCAUGAGCUGGUUCAGCCAGAUCCUGAUCGGCACCCUGCUGAUG UGGCUGGGCCUGAACACCAAGAACGGCAGCAUCUCCCUGAUGUGCCUGGCUCUGGGAG GCGUGCUGAUCUUCCUGAGCACAGCCGUGUCUGCCUGAUAAUAGGCUGGAGCCUCGGU GGCCUAGCUUCUUGCCCCUUGGGCCUCCCCCCAGCCCCUCCUCCCCUUCCUGCACCCGU ACCCCCGUGGUCUUUGAAUAAAGUCUGAGUGGGCGGCAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAAAAAA (SEQ ID NO:20)
EXAMPLES
Non-human primates (n=5) were immunized intramuscularly (IM) with a vaccine composition comprising mRNA encoding either an IgE signal peptide fused to a ZIKV prME antigen (mRNA- 1325, SEQ ID NO:X) (a single 200 μg dose, or a 10 μg, 50 μg or 200 μg dose followed by an equivalent boost at week 4, or a JEV signal peptide fused to a ZIKV prME antigen (mRNA-1893, SEQ ID NO:X) (a 10 μg followed by an equivalent boost at week 4). Animals were challenged at week 8 with 1000 focus-forming units (FFU) of Zika virus. Serum was collected 3, 4, 5, 6 and 7 days post challenge. The data in FIG. 1 shows that while a single 200 μg dose of the mRNA-1325 vaccine conferred nearly complete protection, the mRNA-1893 vaccine unexpectedly provided sterilizing immunity at a 20 fold lower dose. Neutralizing antibody titers (EC50 fold change relative to week 8) are shown in FIG. 2. mRNA-1325
MDWTWILFLVAAATRVHSVEVTRRGSAYYMYLDRSDAGEAISFPTTLGMNKCYIQIMDLGH MCDATMSYECPMLDEGVEPDDVDCWCNTTSTWVVYGTCHHKKGEARRSRRAVTLPSHSTR KLQTRSQTWLESREYTKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPA YSIRCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPAVDIELVTTTVSNMAEVRSY CYEASISDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNGCGLFGKGSLVTCAKFA CSKKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGF GSLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALV EFKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDKLRLKG VSYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPV ITESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGD TAWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLVWLGLNTKNGSISLTCL ALGGVLIFLSTAVSA (SEQ ID NO: 17) mRNA-1893
MWLVSLAIVTACAGAAEVTRRGSAYYMYLDRNDAGEAISFPTTLGMNKCYIQIMDLGHMC DATMSYECPMLDEGVEPDDVDCWCNTTSTWVVYGTCHHKKGEARRSRRAVTLPSHSTRKL QTRSQTWLESREYTKHLIRVENWIFRNPGFALAAAAIAWLLGSSTSQKVIYLVMILLIAPAYSI RCIGVSNRDFVEGMSGGTWVDVVLEHGGCVTVMAQDKPTVDIELVTTTVSNMAEVRSYCY EASISDMASDSRCPTQGEAYLDKQSDTQYVCKRTLVDRGWGNGCGLFGKGSLVTCAKFACS KKMTGKSIQPENLEYRIMLSVHGSQHSGMIVNDTGHETDENRAKVEITPNSPRAEATLGGFG SLGLDCEPRTGLDFSDLYYLTMNNKHWLVHKEWFHDIPLPWHAGADTGTPHWNNKEALVE FKDAHAKRQTVVVLGSQEGAVHTALAGALEAEMDGAKGRLSSGHLKCRLKMDKLRLKGV SYSLCTAAFTFTKIPAETLHGTVTVEVQYAGTDGPCKVPAQMAVDMQTLTPVGRLITANPVI TESTENSKMMLELDPPFGDSYIVIGVGEKKITHHWHRSGSTIGKAFEATVRGAKRMAVLGDT AWDFGSVGGALNSLGKGIHQIFGAAFKSLFGGMSWFSQILIGTLLMWLGLNTKNGSISLMCL ALGGVLIFLSTAVSA (SEQ ID NO:7)
All references, patents and patent applications disclosed herein are incorporated by reference with respect to the subject matter for which each is cited, which in some cases may encompass the entirety of the document.
The indefinite articles "a" and "an," as used herein in the specification and in the claims, unless clearly indicated to the contrary, should be understood to mean "at least one."
It should also be understood that, unless clearly indicated to the contrary, in any methods claimed herein that include more than one step or act, the order of the steps or acts of the method is not necessarily limited to the order in which the steps or acts of the method are recited.
In the claims, as well as in the specification above, all transitional phrases such as "comprising," "including," "carrying," "having," "containing," "involving," "holding," "composed of," and the like are to be understood to be open-ended, i.e., to mean including but not limited to. Only the transitional phrases "consisting of and "consisting essentially of shall be closed or semi-closed transitional phrases, respectively, as set forth in the United States Patent Office Manual of Patent Examining Procedures, Section 2111.03.

Claims

CLAIMS What is claimed is:
1. A method comprising administering to a subject a ribonucleic acid (RNA) vaccine comprising an open reading frame (ORF) encoding a JEV signal peptide fused to a Zika virus (ZIKV) prME protein in an effective amount to induce in the subject a ZIKV prME- specific immune response, wherein the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 10-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
2. A method comprising administering to a subject a ribonucleic acid (RNA) vaccine comprising an open reading frame (ORF) encoding a JEV signal peptide fused to a Zika virus (ZIKV) prME protein in an effective amount to reduce viral load in the subject by at least 80%, relative to a control, at 3-7 days following exposure to ZIKV, wherein the control is the viral load in a subject administered a ZIKV RNA vaccine lacking the JEV signal sequence.
3. A method comprising administering to a subject a ribonucleic acid (RNA)vaccine comprising an open reading frame (ORF) encoding a JEV signal peptide fused to a Zika virus (ZIKV) prME protein in an effective amount to induce in the subject a ZIKV prME-specific immune response, wherein efficacy of the RNA vaccine is at least 80% relative to
unvaccinated control subjects.
4. The method of claim 3, wherein the effective amount is sufficient to provide sterilizing immunity in the subject at an at least 20-fold lower dose relative to a ZIKV mRNA vaccine encoding a IgE signal peptide fused to prME.
5. The method of any one of claims 1-4, wherein the effective amount is sufficient to produce detectable levels of ZIKV prME protein as measured in serum of the subject at 1-72 hours post administration.
6. The method of any one of claims 1-5, wherein the effective amount is sufficient to produce a 1,000-10,000 neutralization titer produced by neutralizing antibody against the ZIKV prME protein as measured in serum of the subject at 1-72 hours post administration.
7. The method of any one of claims 1-6, wherein an anti-ZIKV prME protein antibody titer produced in the subject is increased by at least 1 log relative to a control, wherein the control is an anti-ZIKV prME protein antibody titer produced in a subject who has not been administered a vaccine against ZIKV.
8. The method of any one of claims 1-7, wherein the anti-ZIKV prME protein antibody titer produced in the subject is increased at least 2 times relative to a control, wherein the control is an anti-ZIKV prME protein antibody titer produced in a subject who has not been administered a vaccine against ZIKV.
9. The method of any one of claims 1-8, wherein the effective amount is a total dose of 20 μβ-200 μg.
10. The method of any one of claims 1-9, wherein the RNA vaccine comprises at least one modified nucleotide.
11. The method of any one of claims 1-9, wherein the RNA vaccine does not comprise modified nucleotides.
12. The method of any one of claims 1-11, wherein at least 80% of uracil nucleotides in the ORF have a chemical modification selected from Nl-methyl-pseudouridine or Nl-ethyl- pseudouridine.
13. The method of any one of claims 1-12, wherein the RNA vaccine further comprises a 5' untranslated region (UTR) comprising a sequence selected from SEQ ID NO: 13 and SEQ
ID NO: 14.
14. The method of any one of claims 1-13, wherein the RNA vaccine further comprises a 3' UTR comprising a sequence selected from SEQ ID NO: 15 and SEQ ID NO: 16.
15. The method of any one of claims 1-14, wherein the ORF comprises a sequence selected from SEQ ID NOs: 1-6.
16. The method of any one of claims 1-15, wherein the ZIKV prME protein comprises a sequence selected from SEQ ID NOs:7-12.
17. The method of any one of claims 1-16, wherein the JEV signal peptide comprises the sequence of SEQ ID NO: 18.
18. The method of any one of claims 1-17, wherein the RNA vaccine is formulated in a lipid nanoparticle.
19. The method of claim 18, wherein the lipid nanoparticle comprises a molar ratio of 20- 60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG- modified lipid
20. The method of claim 19, wherein the ionizable cationic lipid comprises the following compound:
Figure imgf000023_0001
21. The method of any one of claims 1-20, wherein the RNA vaccine is a messenger RNA (mRNA) vaccine.
22. The method of any one of claims 1-21, wherein the vaccine comprises the sequence of SEQ ID NO:20 or an sequence that is at least 95% identical to the sequence of SEQ ID
NO:20.
23. A ribonucleic acid (RNA) vaccine comprising a 5' untranslated region (UTR), an open reading frame (ORF) encoding a JEV signal peptide fused to a Zika virus (ZIKV) prME protein, and a 3' UTR.
24. The RNA vaccine of claim 23, wherein the 5' UTR comprises a sequence selected from SEQ ID NO: 13 and SEQ ID NO: 14.
25. The RNA vaccine of claim 23 or 24, wherein the ORF comprises a sequence selected from SEQ ID NOs: l-6
26. The RNA vaccine of any one of claims 23-25, wherein the 3' UTR comprises a sequence selected from SEQ ID NO: 15 and SEQ ID NO: 16.
27. The RNA vaccine of any one of claims 23-26, wherein the ZIKV prME protein comprises a sequence selected from SEQ ID NOs:7-12.
28. The RNA vaccine of any one of claims 23-27, wherein the JEV signal peptide comprises the sequence of SEQ ID NO: 18.
29. The RNA vaccine of any one of claims 23-28, wherein the RNA vaccine comprises at least one modified nucleotide.
30. The RNA vaccine of any one of claims 23-28, wherein the RNA vaccine does not comprise modified nucleotides.
31. The RNA vaccine of any one of claims 23-30, wherein at least 80% of the uracil in the ORF have a chemical modification selected from Nl-methyl-pseudouridine or Nl-ethyl- pseudouridine, optionally wherein the chemical modification is in the 5-position of the uracil.
32. The RNA vaccine of any one of claims 23-31, wherein the RNA vaccine is formulated in a lipid nanoparticle.
33. The RNA vaccine of claim 32, wherein the lipid nanoparticle comprises a molar ratio of 20-60% ionizable cationic lipid, 5-25% non-cationic lipid, 25-55% sterol, and 0.5-15% PEG-modified lipid
34. The RNA vaccine of claim 33, wherein the ionizable cationic lipid comprises the following compound:
Figure imgf000025_0001
35. The RNA vaccine of any one of claims 23-34, wherein the RNA vaccine is a messenger RNA (mRNA) vaccine.
36. The RNA vaccine of any one of claims 23-25 comprising a sequence that is at least 95% identical to the sequence of SEQ ID NO:20.
37. The RNA vaccine of claim 36, wherein the sequence is at least 98% identical to the sequence of SEQ ID NO:20.
38. The RNA vaccine of claim 37, wherein the sequence comprises SEQ ID NO:20.
PCT/US2018/051120 2017-09-14 2018-09-14 Zika virus rna vaccines WO2019055807A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP18855540.3A EP3681514A4 (en) 2017-09-14 2018-09-14 Zika virus rna vaccines

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762558746P 2017-09-14 2017-09-14
US62/558,746 2017-09-14

Publications (1)

Publication Number Publication Date
WO2019055807A1 true WO2019055807A1 (en) 2019-03-21

Family

ID=65723908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/051120 WO2019055807A1 (en) 2017-09-14 2018-09-14 Zika virus rna vaccines

Country Status (4)

Country Link
US (3) US10653767B2 (en)
EP (1) EP3681514A4 (en)
MA (1) MA50253A (en)
WO (1) WO2019055807A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702597B2 (en) 2015-07-21 2020-07-07 Modernatx, Inc. CHIKV RNA vaccines
WO2021211343A1 (en) * 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines
WO2021231929A1 (en) * 2020-05-15 2021-11-18 Modernatx, Inc. Rna formulations for high volume distribution
US11235052B2 (en) 2015-10-22 2022-02-01 Modernatx, Inc. Chikungunya virus RNA vaccines
EP4043031A1 (en) * 2016-11-17 2022-08-17 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
LT3134131T (en) 2014-04-23 2022-02-10 Modernatx, Inc. Nucleic acid vaccines
US11364292B2 (en) 2015-07-21 2022-06-21 Modernatx, Inc. CHIKV RNA vaccines
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
MA46316A (en) 2015-10-22 2021-03-24 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
EP4011451A1 (en) 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
TW201729838A (en) 2015-10-22 2017-09-01 現代公司 Nucleic acid vaccines for varicella zoster virus (VZV)
SI3386484T1 (en) 2015-12-10 2022-06-30 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
ES2928475T3 (en) 2016-09-14 2022-11-18 Modernatx Inc High purity RNA compositions and methods for their preparation
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. Influenza vaccine
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. Respiratory virus nucleic acid vaccines
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
MA52262A (en) 2017-03-15 2020-02-19 Modernatx Inc BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS
MA47790A (en) 2017-03-17 2021-05-05 Modernatx Inc RNA-BASED VACCINES AGAINST ZOONOTIC DISEASES
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
MA49421A (en) 2017-06-15 2020-04-22 Modernatx Inc RNA FORMULATIONS
US20200254086A1 (en) * 2017-08-18 2020-08-13 Moderna TX, Inc. Efficacious mrna vaccines
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. Methods for hplc analysis
CN111212905A (en) 2017-08-18 2020-05-29 摩登纳特斯有限公司 RNA polymerase variants
MA49914A (en) 2017-08-18 2021-04-21 Modernatx Inc HPLC ANALYTICAL PROCESSES
CN111315359A (en) 2017-08-31 2020-06-19 摩登纳特斯有限公司 Method for preparing lipid nanoparticles
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. Zika virus rna vaccines
MA54676A (en) 2018-01-29 2021-11-17 Modernatx Inc RSV RNA VACCINES
US11351242B1 (en) 2019-02-12 2022-06-07 Modernatx, Inc. HMPV/hPIV3 mRNA vaccine composition
US11851694B1 (en) 2019-02-20 2023-12-26 Modernatx, Inc. High fidelity in vitro transcription
MX2021010075A (en) 2019-02-20 2021-12-10 Modernatx Inc Rna polymerase variants for co-transcriptional capping.
AU2021261471A1 (en) 2020-04-22 2022-11-17 BioNTech SE Coronavirus vaccine
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine
WO2022152939A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
US11878055B1 (en) 2022-06-26 2024-01-23 BioNTech SE Coronavirus vaccine

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015463A2 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
WO2017070624A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2018009154A1 (en) * 2016-07-02 2018-01-11 Intel Corporation Rram devices with extended switching layer and methods of fabrication
WO2018132537A1 (en) * 2017-01-11 2018-07-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an immune response against zika virus
WO2018151816A1 (en) * 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions

Family Cites Families (249)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
CA1335429C (en) 1986-03-07 1995-05-02 Geoffrey L. Smith Processes for the production of hcmv glycoproteins, antibodies thereto and hcmv vaccines, and recombinant vectors therefor
US6867195B1 (en) 1989-03-21 2005-03-15 Vical Incorporated Lipid-mediated polynucleotide administration to reduce likelihood of subject's becoming infected
WO1990011092A1 (en) 1989-03-21 1990-10-04 Vical, Inc. Expression of exogenous polynucleotide sequences in a vertebrate
FR2676072B1 (en) 1991-05-03 1994-11-18 Transgene Sa RNA DELIVERY VECTOR.
EP0625049A4 (en) 1992-01-23 1995-07-12 Vical Inc Ex vivo gene transfer.
IL112820A0 (en) 1994-03-07 1995-05-26 Merck & Co Inc Coordinate in vivo gene expression
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
AU2656295A (en) 1994-06-02 1996-01-04 Chiron Corporation Nucleic acid immunization using a virus-based infection/transfection system
EP0855184A1 (en) 1997-01-23 1998-07-29 Grayson B. Dr. Lipford Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
US6251665B1 (en) 1997-02-07 2001-06-26 Cem Cezayirli Directed maturation of stem cells and production of programmable antigen presenting dentritic cells therefrom
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
AU750106B2 (en) 1997-10-07 2002-07-11 University Of Maryland Biotechnology Institute Method for introducing and expressing RNA in animal cells
WO1999033982A2 (en) 1997-12-23 1999-07-08 Chiron Corporation Human genes and gene expression products i
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
WO2000050006A2 (en) 1999-02-26 2000-08-31 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
US6514948B1 (en) 1999-07-02 2003-02-04 The Regents Of The University Of California Method for enhancing an immune response
EP1541690A3 (en) 1999-09-09 2005-07-27 CureVac GmbH Transfer of mRNA using polycationic compounds
AU7398200A (en) 1999-09-17 2001-04-24 Aventis Pasteur Limited Chlamydia antigens and corresponding dna fragments and uses thereof
WO2001023002A1 (en) 1999-09-30 2001-04-05 National Jewish Medical And Research Center Method for inhibition of pathogenic microorganisms
US7060291B1 (en) 1999-11-24 2006-06-13 Transave, Inc. Modular targeted liposomal delivery system
ES2554254T3 (en) 2000-02-16 2015-12-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Chimeras of the immunogenic dengue 2 virus
DE60139690D1 (en) 2000-07-03 2009-10-08 Novartis Vaccines & Diagnostic IMMUNIZATION AGAINST CHLAMYDIA PNEUMONIAE
ATE346947T1 (en) 2000-07-21 2006-12-15 Glaxo Group Ltd CODON-OPTIMIZED PAPILLOMA VIRUS SEQUENCES
DE50211110D1 (en) 2001-04-21 2007-12-06 Curevac Gmbh INJECTION DEVICE FOR mRNA APPLICATION
DE50214200D1 (en) 2001-06-05 2010-03-25 Curevac Gmbh Stabilized tumor antigen mRNA with increased G / C content
DE10162480A1 (en) 2001-12-19 2003-08-07 Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
NZ573064A (en) 2002-04-04 2011-02-25 Coley Pharm Gmbh Immunostimulatory G,U-containing oligoribonucleotides
DE10229872A1 (en) 2002-07-03 2004-01-29 Curevac Gmbh Immune stimulation through chemically modified RNA
CA2508228C (en) 2002-12-23 2013-12-17 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
WO2004076645A2 (en) 2003-02-27 2004-09-10 University Of Massachusetts Compositions and methods for cytomegalovirus treatment
WO2005009346A2 (en) 2003-06-24 2005-02-03 Mirus Corporation Inhibition of gene function by delivery of polynucleotide-based gene expression inhibitors to mammalian cells in vivo
DK1651666T3 (en) 2003-07-11 2009-08-31 Alphavax Inc Alphavirus-based cytomegalovirus vaccines
DE10335833A1 (en) 2003-08-05 2005-03-03 Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
DE10347710B4 (en) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Recombinant vaccines and their use
DE102004035227A1 (en) 2004-07-21 2006-02-16 Curevac Gmbh mRNA mixture for vaccination against tumor diseases
CA2576798C (en) 2004-07-27 2014-09-09 Gwong-Jen J. Chang Localization and characterization of flavivirus envelope glycoprotein cross-reactive epitopes and methods for their use
DE102004042546A1 (en) 2004-09-02 2006-03-09 Curevac Gmbh Combination therapy for immune stimulation
US7976845B2 (en) 2004-11-29 2011-07-12 The Council Of The Queensland Institute Of Medical Research Human cytomegalovirus immunotherapy
WO2006071903A2 (en) 2004-12-28 2006-07-06 Ptc Therapeutics, Inc. Cell based methods and systems for the identification of rna regulatory sequences and compounds that modulate their functions
EP2290363B1 (en) 2005-03-11 2014-01-08 Firalis SAS Biomarkers for cardiovascular side-effects induced by cox-2 inhibitory compounds
TR201909609T4 (en) 2005-08-23 2019-07-22 Univ Pennsylvania DNA containing modified nucleosides and methods of use.
WO2007094854A2 (en) 2005-12-14 2007-08-23 The Board Of Regents Of The University Of Oklahoma Rna virus vaccines and methods
DE102006007433A1 (en) 2006-02-17 2007-08-23 Curevac Gmbh Immunostimulant adjuvant useful in vaccines against cancer or infectious diseases comprises a lipid-modified nucleic acid
AU2007280690C1 (en) 2006-07-31 2012-08-23 Curevac Gmbh Nucleic acid of formula (I): GIXmGn, or (II): CIXmCn, in particular as an immune-stimulating agent/adjuvant
DE102006051516A1 (en) 2006-10-31 2008-05-08 Curevac Gmbh (Base) modified RNA to increase the expression of a protein
DE102007001370A1 (en) 2007-01-09 2008-07-10 Curevac Gmbh RNA-encoded antibodies
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating prostate cancer (pca)
WO2009046738A1 (en) 2007-10-09 2009-04-16 Curevac Gmbh Composition for treating lung cancer, particularly of non-small lung cancers (nsclc)
CN101861165A (en) 2007-10-12 2010-10-13 麻省理工学院 Vaccine nanotechnology
MX2010008468A (en) 2008-01-31 2010-08-30 Curevac Gmbh NUCLEIC ACIDS COMPRISING FORMULA (NuGlX<sub >mGnNv)a AND DERIVATIVES THEREOF AS AN IMMUNOSTIMULATING AGENTS /ADJUVANTS.
PL2279254T3 (en) 2008-04-15 2017-11-30 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
WO2009127230A1 (en) 2008-04-16 2009-10-22 Curevac Gmbh MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
EA021422B1 (en) 2008-06-16 2015-06-30 Бинд Терапьютикс, Инк. Polymeric nanoparticles comprising a therapeutic agent and method of making same
WO2010037408A1 (en) 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
AU2015210364B2 (en) 2008-10-09 2017-03-09 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
EP3225621A1 (en) 2008-10-09 2017-10-04 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
EP4241767A3 (en) 2008-11-10 2023-11-01 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010057203A2 (en) 2008-11-17 2010-05-20 The Board Of Regents Of The University Of Texas System Hdl particles for delivery of nucleic acids
CA2751342C (en) 2009-01-29 2019-05-07 Alnylam Pharmaceuticals, Inc. Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid
WO2010088927A1 (en) 2009-02-09 2010-08-12 Curevac Gmbh Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
RU2600798C2 (en) 2009-04-01 2016-10-27 Юниверсити Оф Майами Vaccine compositions and methods of use thereof
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
CA2766907A1 (en) 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
US20110053829A1 (en) 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US8691961B1 (en) 2009-11-09 2014-04-08 Integral Molecular, Inc. Flavivirus reporter virus and methods of making and using the same
LT2506857T (en) 2009-12-01 2018-07-10 Translate Bio, Inc. Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases
WO2011069529A1 (en) 2009-12-09 2011-06-16 Curevac Gmbh Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
EP2387999A1 (en) 2010-05-21 2011-11-23 CureVac GmbH Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
WO2012006378A1 (en) 2010-07-06 2012-01-12 Novartis Ag Liposomes with lipids having an advantageous pka- value for rna delivery
BR112013000392B8 (en) 2010-07-06 2022-10-04 Novartis Ag PHARMACEUTICAL COMPOSITION CONTAINING VIRION-LIKE DISTRIBUTION PARTICLE FOR SELF-REPLICATING RNA MOLECULES AND THEIR USE
CA2804591C (en) 2010-07-06 2019-01-22 Novartis Ag Cationic oil-in-water emulsions
PT2591114T (en) 2010-07-06 2016-08-02 Glaxosmithkline Biologicals Sa Immunisation of large mammals with low doses of rna
US8968746B2 (en) 2010-07-30 2015-03-03 Curevac Gmbh Complexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
WO2012019630A1 (en) 2010-08-13 2012-02-16 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
BR112013004865A2 (en) 2010-08-31 2016-06-07 Novartis Ag lipids suitable for liposomal delivery of rna protein coders
PT4008357T (en) 2010-08-31 2023-01-11 Glaxosmithkline Biologicals Sa Small liposomes for delivery of immunogen-encoding rna
LT4066855T (en) 2010-08-31 2023-03-10 Glaxosmithkline Biologicals Sa Pegylated liposomes for delivery of immunogen-encoding rna
PL3590949T3 (en) 2010-10-01 2022-08-29 Modernatx, Inc. Ribonucleic acids containing n1-methyl-pseudouracils and uses thereof
WO2012075040A2 (en) 2010-11-30 2012-06-07 Shire Human Genetic Therapies, Inc. mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES
WO2012089225A1 (en) 2010-12-29 2012-07-05 Curevac Gmbh Combination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012099805A2 (en) 2011-01-19 2012-07-26 Ocean Nanotech, Llc Nanoparticle based immunological stimulation
WO2012116715A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in newborns and infants
WO2012113413A1 (en) 2011-02-21 2012-08-30 Curevac Gmbh Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en) 2011-03-02 2012-09-07 Curevac Gmbh Vaccination in elderly patients
AU2012236099A1 (en) 2011-03-31 2013-10-03 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
BR112013029490A2 (en) 2011-05-17 2019-09-24 Moderna Therapeutics Inc engineered nucleic acids and methods of use for non-human vertebrates
CA2873404C (en) 2011-06-02 2022-08-30 The Regents Of The University Of California Membrane encapsulated nanoparticles and method of use
PT2717893T (en) 2011-06-08 2019-08-20 Translate Bio Inc Lipid nanoparticle compositions and methods for mrna delivery
US8916696B2 (en) 2011-06-12 2014-12-23 City Of Hope Aptamer-mRNA conjugates for targeted protein or peptide expression and methods for their use
ES2656050T3 (en) 2011-07-06 2018-02-22 Glaxosmithkline Biologicals Sa Immunogenic combination compositions and uses thereof
EP3424495A1 (en) 2011-07-06 2019-01-09 GlaxoSmithKline Biologicals S.A. Oil-in-water emulsions that contain nucleic acids
RU2649133C2 (en) 2011-07-06 2018-03-29 Новартис Аг Cationic oil-in-water emulsions
CA2841047A1 (en) 2011-07-06 2013-01-10 Novartis Ag Immunogenic compositions and uses thereof
CN103930547A (en) 2011-09-02 2014-07-16 诺华股份有限公司 Organic compositions to treat HSF1-related diseases
EP3384938A1 (en) 2011-09-12 2018-10-10 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6305925B2 (en) 2011-10-11 2018-04-18 ノバルティス アーゲー Recombinant self-replicating polycistronic RNA molecules
JP2014532071A (en) 2011-10-14 2014-12-04 エスティーシー. ユーエヌエムStc.Unm Lipid bilayer (protocell) supported on porous nanoparticles for targeted delivery including transdermal delivery of cargo and method thereof
CN103987847B (en) 2011-10-18 2017-06-16 迪克纳制药公司 Amine cation lipid and application thereof
WO2013086373A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
US20140378538A1 (en) 2011-12-14 2014-12-25 Moderma Therapeutics, Inc. Methods of responding to a biothreat
EP2791159A4 (en) 2011-12-14 2015-10-14 Moderna Therapeutics Inc Modified nucleic acids, and acute care uses thereof
LT2791160T (en) 2011-12-16 2022-06-10 Modernatx, Inc. Modified mrna compositions
RU2014129863A (en) 2011-12-21 2016-02-10 Модерна Терапьютикс, Инк. WAYS TO INCREASE VITALITY OR INCREASE THE LIFE OF A BODY OR EXPLANATE BODY
DK3421601T3 (en) 2011-12-30 2020-02-24 Cellscript Llc Preparation and use of in vitro synthesized ssRNA for introduction into mammalian cells to induce a biological or biochemical effect
WO2013113325A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation
WO2013120499A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
US10322089B2 (en) 2012-03-14 2019-06-18 The Board Of Trustees Of The Leland Stanford Junior University Nanoparticles, nanoparticle delivery methods, and systems of delivery
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US10501513B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
AU2013243951A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of secreted proteins
EP3498267A1 (en) 2012-05-25 2019-06-19 CureVac AG Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
JP6561378B2 (en) 2012-06-08 2019-08-21 トランスレイト バイオ, インコーポレイテッド Transpulmonary delivery of mRNA to non-pulmonary target cells
WO2014028429A2 (en) 2012-08-14 2014-02-20 Moderna Therapeutics, Inc. Enzymes and polymerases for the synthesis of rna
US9267114B2 (en) 2012-11-07 2016-02-23 Southern Research Institute Flavivirus envelope protein mutations affecting virion disassembly
WO2014071963A1 (en) 2012-11-09 2014-05-15 Biontech Ag Method for cellular rna expression
AU2013343864B2 (en) 2012-11-09 2019-04-04 BioNTech SE Method for cellular RNA expression
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドModernaTX,Inc. Chemically modified mRNA
US20150366997A1 (en) 2012-12-07 2015-12-24 Shire Human Genetics Therapies, Inc. COMPOSITIONS AND METHODS FOR mRNA DELIVERY
AU2013355258A1 (en) 2012-12-07 2015-06-11 Alnylam Pharmaceuticals, Inc. Improved nucleic acid lipid particle formulations
US20150315541A1 (en) 2012-12-13 2015-11-05 Moderna Therapeutics, Inc. Modified polynucleotides for altering cell phenotype
EP2931319B1 (en) 2012-12-13 2019-08-21 ModernaTX, Inc. Modified nucleic acid molecules and uses thereof
ES2739913T3 (en) 2013-02-22 2020-02-04 Curevac Ag Combination of vaccination and inhibition of the PD-1 route
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
WO2014160243A1 (en) 2013-03-14 2014-10-02 The Trustees Of The University Of Pennsylvania Purification and purity assessment of rna molecules synthesized with modified nucleosides
EA201591293A1 (en) 2013-03-14 2016-02-29 Шир Хьюман Дженетик Терапис, Инк. METHODS AND COMPOSITIONS FOR DELIVERY OF ANTIBODIES CODED BY mRNAs
EP2971161B1 (en) 2013-03-15 2018-12-26 ModernaTX, Inc. Ribonucleic acid purification
WO2014144039A1 (en) 2013-03-15 2014-09-18 Moderna Therapeutics, Inc. Characterization of mrna molecules
US10590161B2 (en) 2013-03-15 2020-03-17 Modernatx, Inc. Ion exchange purification of mRNA
EP2971033B8 (en) 2013-03-15 2019-07-10 ModernaTX, Inc. Manufacturing methods for production of rna transcripts
HUE039189T2 (en) 2013-03-15 2018-12-28 Translate Bio Inc Synergistic enhancement of the delivery of nucleic acids via blended formulations
TW201534578A (en) 2013-07-08 2015-09-16 Daiichi Sankyo Co Ltd Novel lipid
CA2919353C (en) 2013-07-25 2022-08-23 Avatar Medical, Llc Conformationally stabilized rsv pre-fusion f proteins
ES2702466T3 (en) 2013-08-21 2019-03-01 Curevac Ag Procedure to increase the expression of proteins encoded by RNA
AU2014310934B2 (en) 2013-08-21 2019-09-12 CureVac SE Respiratory syncytial virus (RSV) vaccine
WO2015051169A2 (en) 2013-10-02 2015-04-09 Moderna Therapeutics, Inc. Polynucleotide molecules and uses thereof
AU2014337156A1 (en) 2013-10-18 2016-05-12 Modernatx, Inc. Compositions and methods for tolerizing cellular systems
WO2015130584A2 (en) 2014-02-25 2015-09-03 Merck Sharp & Dohme Corp. Lipid nanoparticle vaccine adjuvants and antigen delivery systems
DK3113795T3 (en) 2014-03-01 2019-10-21 Univ Texas RECOMBINANT VIRAL ISFAHAN VECTORS
LT3134131T (en) 2014-04-23 2022-02-10 Modernatx, Inc. Nucleic acid vaccines
MX2016016533A (en) 2014-06-13 2017-05-01 Glaxosmithkline Biologicals Sa Immunogenic combinations.
WO2015196128A2 (en) 2014-06-19 2015-12-23 Moderna Therapeutics, Inc. Alternative nucleic acid molecules and uses thereof
WO2016011306A2 (en) 2014-07-17 2016-01-21 Moderna Therapeutics, Inc. Terminal modifications of polynucleotides
KR20170066433A (en) 2014-09-17 2017-06-14 더 유니버시티 오브 아이오와 리서치 파운데이션 Viral rna segments as immunomodulatory agents and vaccine components
EP3031822A1 (en) 2014-12-08 2016-06-15 Novartis AG Cytomegalovirus antigens
WO2016118724A1 (en) 2015-01-21 2016-07-28 Moderna Therapeutics, Inc. Lipid nanoparticle compositions
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
WO2016164762A1 (en) 2015-04-08 2016-10-13 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor egf-a and intracellular domain mutants and methods of using the same
WO2016176330A1 (en) 2015-04-27 2016-11-03 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an adaptive immune response
SG11201708652YA (en) 2015-05-15 2017-11-29 Curevac Ag Prime-boost regimens involving administration of at least one mrna construct
WO2016201377A1 (en) 2015-06-10 2016-12-15 Moderna Therapeutics, Inc. Targeted adaptive vaccines
WO2016203025A1 (en) 2015-06-17 2016-12-22 Curevac Ag Vaccine composition
WO2017015457A1 (en) 2015-07-21 2017-01-26 Modernatx, Inc. Ebola vaccine
WO2017019935A1 (en) 2015-07-30 2017-02-02 Modernatx, Inc. Multimeric mrna
EP3328394A4 (en) 2015-07-30 2019-03-13 ModernaTX, Inc. Concatemeric peptide epitope rnas
EP3331555A1 (en) 2015-08-05 2018-06-13 CureVac AG Epidermal mrna vaccine
US20180237849A1 (en) 2015-08-17 2018-08-23 Modernatx, Inc. Rna mapping/fingerprinting
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
ES2969082T3 (en) 2015-09-17 2024-05-16 Modernatx Inc Compounds and compositions for intracellular administration of therapeutic agents
EP3359670B2 (en) 2015-10-05 2024-02-14 ModernaTX, Inc. Methods for therapeutic administration of messenger ribonucleic acid drugs
WO2017066789A1 (en) 2015-10-16 2017-04-20 Modernatx, Inc. Mrna cap analogs with modified sugar
MA46317A (en) 2015-10-22 2019-08-07 Modernatx Inc RESPIRATORY SYNCYTIAL VIRUS VACCINE
TW201729838A (en) 2015-10-22 2017-09-01 現代公司 Nucleic acid vaccines for varicella zoster virus (VZV)
PE20181531A1 (en) 2015-10-22 2018-09-26 Modernatx Inc SIMPLE HERPES VIRUS VACCINE
EP4011451A1 (en) * 2015-10-22 2022-06-15 ModernaTX, Inc. Metapneumovirus mrna vaccines
CA3003103A1 (en) 2015-10-22 2017-04-27 Modernatx, Inc. Broad spectrum influenza virus vaccine
CN108430456B (en) 2015-10-22 2022-01-18 摩登纳特斯有限公司 Cancer vaccine
MA45209A (en) 2015-10-22 2019-04-17 Modernatx Inc VACCINES AGAINST SEXUALLY TRANSMITTED DISEASES
MA46316A (en) 2015-10-22 2021-03-24 Modernatx Inc HUMAN CYTOMEGALOVIRUS VACCINE
EP3368507B1 (en) 2015-10-28 2022-12-07 Acuitas Therapeutics Inc. Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids
SI3386484T1 (en) 2015-12-10 2022-06-30 Modernatx, Inc. Compositions and methods for delivery of therapeutic agents
AU2016369612B2 (en) 2015-12-17 2023-06-01 Modernatx, Inc. Polynucleotides encoding methylmalonyl-CoA mutase
US10465190B1 (en) 2015-12-23 2019-11-05 Modernatx, Inc. In vitro transcription methods and constructs
EP3184119A1 (en) 2015-12-23 2017-06-28 Themis Bioscience GmbH Chromatography based purification strategies for measles scaffold based viruses
WO2017127750A1 (en) 2016-01-22 2017-07-27 Modernatx, Inc. Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof
SG10201913630YA (en) 2016-02-17 2020-03-30 Curevac Ag Zika virus vaccine
CN109152826B (en) 2016-02-25 2022-11-04 宾夕法尼亚大学理事会 Novel vaccine against Zika virus
WO2017165317A2 (en) 2016-03-20 2017-09-28 Samuel Bogoch Therapies, vaccines, and predictive methods for flaviviruses
WO2017162265A1 (en) 2016-03-21 2017-09-28 Biontech Rna Pharmaceuticals Gmbh Trans-replicating rna
WO2017201347A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
US20190390181A1 (en) 2016-05-18 2019-12-26 Modernatx, Inc. Polynucleotides Encoding Lipoprotein Lipase for the Treatment of Hyperlipidemia
WO2017201317A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polyribonucleotides containing reduced uracil content and uses thereof
WO2017201342A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding jagged1 for the treatment of alagille syndrome
WO2017201332A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding acyl-coa dehydrogenase, very long-chain for the treatment of very long-chain acyl-coa dehydrogenase deficiency
MA45041A (en) 2016-05-18 2019-03-27 Modernatx Inc POLYNUCLEOTIDES CODING FOR GALACTOSE-1-PHOSPHATE URIDYLYLTRANSFERASE FOR THE TREATMENT OF TYPE 1 GALACTOSEMIA
CA3024625A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding citrin for the treatment of citrullinemia type 2
CA3024500A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Polynucleotides encoding relaxin
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
US20200085916A1 (en) 2016-05-18 2020-03-19 Modernatx, Inc. Polynucleotides encoding porphobilinogen deaminase for the treatment of acute intermittent porphyria
AU2017266932B2 (en) 2016-05-18 2023-04-20 Modernatx, Inc. Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease
US11033615B2 (en) 2016-05-31 2021-06-15 The Government of the United States, As Represented by the Secretary of the Army Fort Detrick, Maryland Zika virus vaccine and methods of production
MX2021010105A (en) 2016-06-01 2022-06-16 Infectious Disease Res Inst Nanoalum particles containing a sizing agent.
US10967057B2 (en) 2016-06-02 2021-04-06 Glaxosmithkline Biologicals S.A. Zika viral antigen constructs
AU2017286606A1 (en) 2016-06-14 2018-12-13 Modernatx, Inc. Stabilized formulations of lipid nanoparticles
GB201613191D0 (en) 2016-07-29 2016-09-14 Univ Oxford Innovation Ltd Zika virus vaccine
ES2928475T3 (en) 2016-09-14 2022-11-18 Modernatx Inc High purity RNA compositions and methods for their preparation
US10898566B2 (en) 2016-09-19 2021-01-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zika virus vaccines
CA3041307A1 (en) 2016-10-21 2018-04-26 Giuseppe Ciaramella Human cytomegalovirus vaccine
EP3532613A4 (en) 2016-10-26 2020-05-06 ModernaTX, Inc. Methods and compositions for rna mapping
MX2019004913A (en) 2016-10-26 2019-09-16 Curevac Ag Lipid nanoparticle mrna vaccines.
SG11201903674YA (en) 2016-10-26 2019-05-30 Modernatx Inc Messenger ribonucleic acids for enhancing immune responses and methods of use thereof
EP3538146A4 (en) 2016-11-11 2020-07-15 ModernaTX, Inc. Influenza vaccine
EP3541416A1 (en) 2016-11-17 2019-09-25 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
EP3551193A4 (en) 2016-12-08 2020-08-19 Modernatx, Inc. Respiratory virus nucleic acid vaccines
EP3555289A1 (en) 2016-12-13 2019-10-23 ModernaTX, Inc. Rna affinity purification
US20180243225A1 (en) 2017-01-25 2018-08-30 Modernatx, Inc. Ebola/marburg vaccines
EP3577221A4 (en) 2017-02-01 2020-12-23 ModernaTX, Inc. Polynucleotide secondary structure
MX2019009070A (en) 2017-02-01 2019-10-30 Modernatx Inc Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides.
SG10202108307YA (en) 2017-02-01 2021-08-30 Modernatx Inc Rna cancer vaccines
WO2018157009A1 (en) 2017-02-24 2018-08-30 Modernatx, Inc. Nucleic acid-based therapy of muscular dystrophies
WO2018170256A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Herpes simplex virus vaccine
US11045540B2 (en) 2017-03-15 2021-06-29 Modernatx, Inc. Varicella zoster virus (VZV) vaccine
US11464848B2 (en) 2017-03-15 2022-10-11 Modernatx, Inc. Respiratory syncytial virus vaccine
MA52262A (en) 2017-03-15 2020-02-19 Modernatx Inc BROAD SPECTRUM VACCINE AGAINST THE INFLUENZA VIRUS
FI3596041T3 (en) 2017-03-15 2023-01-31 Compound and compositions for intracellular delivery of therapeutic agents
MA47790A (en) 2017-03-17 2021-05-05 Modernatx Inc RNA-BASED VACCINES AGAINST ZOONOTIC DISEASES
WO2018175783A1 (en) 2017-03-22 2018-09-27 Modernatx, Inc. Rna bacterial vaccines
US11905525B2 (en) 2017-04-05 2024-02-20 Modernatx, Inc. Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins
WO2018200737A1 (en) 2017-04-26 2018-11-01 Modernatx, Inc. Herpes simplex virus vaccine
MA49421A (en) 2017-06-15 2020-04-22 Modernatx Inc RNA FORMULATIONS
WO2018232355A1 (en) 2017-06-15 2018-12-20 Modernatx, Inc. Rna antibodies
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. Methods for hplc analysis
US20200254086A1 (en) 2017-08-18 2020-08-13 Moderna TX, Inc. Efficacious mrna vaccines
MA49914A (en) 2017-08-18 2021-04-21 Modernatx Inc HPLC ANALYTICAL PROCESSES
CN111212905A (en) 2017-08-18 2020-05-29 摩登纳特斯有限公司 RNA polymerase variants
WO2019055807A1 (en) 2017-09-14 2019-03-21 Modernatx, Inc. Zika virus rna vaccines
US20190192646A1 (en) 2017-11-03 2019-06-27 Modernatx, Inc. Salmonella vaccines
CA3083102A1 (en) 2017-11-21 2019-05-31 Modernatx, Inc. Epstein-barr virus vaccines
MA54676A (en) 2018-01-29 2021-11-17 Modernatx Inc RSV RNA VACCINES
KR20210038886A (en) 2018-06-27 2021-04-08 모더나티엑스, 인크. Personalized cancer vaccine epitope selection
WO2020056370A1 (en) 2018-09-13 2020-03-19 Modernatx, Inc. Modified mrna for the treatment of progressive familial intrahepatic cholestasis disorders
JP7410135B2 (en) 2018-09-19 2024-01-09 モデルナティエックス インコーポレイテッド Compounds and compositions for intracellular delivery of therapeutic agents
US20220047518A1 (en) 2018-09-19 2022-02-17 Moderna TX, Inc. Peg lipids and uses thereof
EP3853305A1 (en) 2018-09-19 2021-07-28 ModernaTX, Inc. High-purity peg lipids and uses thereof
WO2020097291A1 (en) 2018-11-07 2020-05-14 Modernatx, Inc. Rna cancer vaccines
MX2021010075A (en) 2019-02-20 2021-12-10 Modernatx Inc Rna polymerase variants for co-transcriptional capping.
AU2020239037A1 (en) 2019-03-11 2021-09-30 Modernatx, Inc. Fed-batch in vitro transcription process
US20220241399A1 (en) 2019-03-15 2022-08-04 Moderna TX, Inc. Hiv rna vaccines
WO2020243561A1 (en) 2019-05-31 2020-12-03 Modernatx, Inc. Expanded t cell assay
US20220348900A1 (en) 2019-08-14 2022-11-03 Modernatx, Inc. Processes for purifying downstream products of in vitro transcription
CA3154082A1 (en) 2019-09-11 2021-03-18 Modernatx, Inc. Human cytomegalovirus vaccine
AU2020348860A1 (en) 2019-09-19 2022-04-07 Modernatx, Inc. Cap guides and methods of use thereof for RNA mapping

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017015463A2 (en) * 2015-07-21 2017-01-26 Modernatx, Inc. Infectious disease vaccines
WO2017070624A1 (en) * 2015-10-22 2017-04-27 Modernatx, Inc. Tropical disease vaccines
WO2018009154A1 (en) * 2016-07-02 2018-01-11 Intel Corporation Rram devices with extended switching layer and methods of fabrication
WO2018132537A1 (en) * 2017-01-11 2018-07-19 The Trustees Of The University Of Pennsylvania Nucleoside-modified rna for inducing an immune response against zika virus
WO2018151816A1 (en) * 2017-02-16 2018-08-23 Modernatx, Inc. High potency immunogenic compositions

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHAHAL J.S. ET AL.: "An RNA nanoparticle vaccine against Zika virus elicits antibody and CD 8+ T cell responses in a mouse model", SCI REP., vol. 7, no. 1, 21 March 2017 (2017-03-21), pages 252, XP055392682, DOI: doi:10.1038/s41598-017-00193-w *
DOWD, K.A. ET AL.: "Rapid Development of a DNA Vaccine for Zika Virus", SCIENCE, vol. 354, no. 6309, 2016, pages 237 - 240, XP055392574, ISSN: 1095-9203, DOI: 10.1126/science.aai3197 *
PARDI, N. ET AL.: "Zika virus protection by a single low-dose nucleoside-moditied mRNA vaccination", NATURE, vol. 543, 9 March 2017 (2017-03-09), pages 248 - 251, XP055370679, ISSN: 0028-0836, DOI: 10.1038/nature21428 *
RICHNER J.M. ET AL.: "Modified mRNA vaccines protect against Zika virus infection", CELL, vol. 168, no. 6, 9 March 2017 (2017-03-09), pages 1114 - 1125, XP055550333, DOI: doi:10.1016/j.cell.2017.02.017 *
RICHNER J.M. ET AL.: "Vaccine mediated protection against Zika virus-induced congenital disease", CELL, vol. 170, no. 2, 13 July 2017 (2017-07-13), pages 273 - 283, XP085125818, DOI: doi:10.1016/j.cell.2017.06.040 *
See also references of EP3681514A4 *
WONG G ET AL.: "An mRNA-based vaccine strategy against Zika", CELL RESEARCH, vol. 27, no. 9, September 2017 (2017-09-01), pages 1077 - 1078, XP055583400, ISSN: 1001-0602, DOI: 10.1038/cr.2017.53 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702597B2 (en) 2015-07-21 2020-07-07 Modernatx, Inc. CHIKV RNA vaccines
US11235052B2 (en) 2015-10-22 2022-02-01 Modernatx, Inc. Chikungunya virus RNA vaccines
EP4043031A1 (en) * 2016-11-17 2022-08-17 GlaxoSmithKline Biologicals SA Zika viral antigen constructs
US11780885B2 (en) 2016-11-17 2023-10-10 Glaxosmithkline Biologicals Sa Zika viral antigen constructs
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
WO2021211343A1 (en) * 2020-04-13 2021-10-21 Modernatx, Inc. Zika virus mrna vaccines
WO2021231929A1 (en) * 2020-05-15 2021-11-18 Modernatx, Inc. Rna formulations for high volume distribution
WO2021231963A1 (en) * 2020-05-15 2021-11-18 Modernatx, Inc. Rna formulations for high volume distribution, and methods of using the same for treating covid-19

Also Published As

Publication number Publication date
MA50253A (en) 2020-07-22
EP3681514A4 (en) 2021-07-14
US20190099481A1 (en) 2019-04-04
US10653767B2 (en) 2020-05-19
US11207398B2 (en) 2021-12-28
EP3681514A1 (en) 2020-07-22
US20220175906A1 (en) 2022-06-09
US20200276296A1 (en) 2020-09-03

Similar Documents

Publication Publication Date Title
US10653767B2 (en) Zika virus MRNA vaccines
US10675342B2 (en) Chikungunya virus RNA vaccines
Richner et al. Vaccine mediated protection against Zika virus-induced congenital disease
Richner et al. Modified mRNA vaccines protect against Zika virus infection
Ikegami et al. Rift valley fever vaccines
RU2209082C2 (en) Chimeric flaviviral vaccines
EP1896069B1 (en) Inactivated chimeric vaccines and related methods of use
CN109843323B (en) Compositions and methods for flavivirus vaccination
US8968996B2 (en) Compositions and methods for rapid immunization against dengue virus
US20110165230A1 (en) Attenuated live vaccines
US9439935B2 (en) Recombinant rift valley fever (RVF) viruses and methods
Tretyakova et al. Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice
CN113151184A (en) Method for cell membrane-based display of coronavirus immunogens to induce neutralizing antibodies
CA3168673A1 (en) Coronavirus vaccines
KR20160027019A (en) Methods and compositions for dengue virus vaccines
US20230149528A1 (en) Development of mosaic vaccines against foot and mouth disease virus serotype o
KR102365464B1 (en) Development of recombinant subunit Zika virus vaccine and preparing method thereof
US11739348B2 (en) Recombinant vectors encoding Zika virus protein subunits
EP4378475A1 (en) Recombinant antigen for inducing an immune response against the zika virus
López et al. New evidence on the virus capsid as a vaccine candidate against the Dengue 2 virus without the induction of the neutralizing antibodies
CN115651071A (en) Antigen fragment and truncation of recombinant protein of feline herpesvirus type I HR-1 strain and application of antigen fragment and truncation in vaccine
Webb Development of improved dengue 2 antigen configurations for a Venezuelan equine encephalitis virus replicon particle-launched dengue vaccine

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18855540

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018855540

Country of ref document: EP

Effective date: 20200414